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Background: Interruption of cardiac stromal cell-derived factor 1 (SDF1)-CXCR4 
axis by chronic AMD3100 administration increased myocardial injury after permanent 
coronary artery ligation, demonstrating the important role of this chemokine in cardiac 
regeneration. 
Hypothesis: Cardiomyocyte-specific conditional overexpression of SDF prevents 
heart failure after permanent coronary ligation and facilitates cardiac regeneration.  
Methods and Results: Tetracycline-controlled, myosine heavy chain promoter 
directed overexpression of cardiac SDF resulted in a significant increase of SDF expression 
(SDF: 8.1 ng / g protein) compared with littermate WT mice (0.02 ng / g protein) four 
weeks after doxycycline withdrawal. SDF overexpression increased AKT and casein 
kinase 1 levels in the heart. Although there was no difference in cardiac function and scar 
 vi 
size one week after infarction, SDF overexpression improved left ventricular (LV) ejection 
fraction (47±5% vs. 29±4%, p<0.05) decreased end-diastolic volume (78±10 vs. 158±30, 
p<0.05) and reduced infarct size measured by trichrome staining (SDF): 13±3% vs. WT 
(n=15): 23±3% of LV wall, p<0.05) four weeks after permanent ligation. 
Bromodeoxyuridine (BrdU) staining revealed increased regeneration indicated by a 5-fold 
increase in BrdU+ / α-sarcomeric actin+-cells in the border zone of the infarct (22±3% 
cardiomyocyte (CM) nuclei vs. 5±1% CM nuclei, p<0.01). Increased proliferation in SDF 
mice was confirmed by a higher number of Ki67+ cells compared to WT mice. 
Cardiomyocyte cross sectional area in the border zone was significantly reduced in SDF 
mice (375±13 μm2 vs. 434±10 μm2, p<0.001) while capillary density remained unchanged 
(2348±151 / mm2 vs. 2498±153 / mm2) compared to WT mice.  
Conclusion: This study demonstrates that cardiac-specific overexpression of SDF 
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Coronary artery disease resulting in myocardial infarction or ischemic 
cardiomyopathy presently remains one of the major causes of death. In the US one in four 
patients who suffered from myocardial infarction, dies due to heart failure. Heart failure in 
this context is the consequence of replacement of contractile myocytes with either fibrotic 
or scar tissue, resulting in an irreversible loss of functional tissue.  
More than 10 years ago a major shift occurred in our understanding of cardiac 
physiology: Dr. Pierro Anversa has provided evidence to support the concept that the heart 
is not a post-mitotic organ and that myocyte turnover continues with the formation of new 
myocytes beyond the neonatal age in mammals.1,2 These initial observations suggests that 
the myocardium might have the potential to regenerate after ischemic injury by either 
activation of endogenous repair mechanisms or transplantation of stem cells. The vast 
number of patients suffering from heart failure after myocardial infarction demonstrates 
that endogenous repair mechanisms are obviously not sufficient to repair or regenerate lost 
myocardium, thus laying the groundwork for further exogenous therapeutic treatment to 
increase effectiveness. Stem cell therapy utilizing different types of stem cells, 
combinations of different cells, and different routes of stem cell administration have been 
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reported recently.3,4 However, the most significant increase in myocardial ejection fraction 
(i.e. the most important variable of myocardial function) is achieved by transplantation of 
autologous c-kit+ cardiac stem cells in patients with ischemic cardiomyopathy.5 
Nevertheless, transplantation of stem cells of any kind includes several caveats: 
a) The number of cells remaining in the heart after transplantation is minimal. Using 
a highly sensitive RT-PCR method for detection of remaining cardiac stem cells after intra-
myocardial injection, revealed that only 43% of those cells stayed in the heart five minutes 
after injection, and that this number further decreased to eight percent (one day) and one 
percent (35 days) after injection, respectively. Unpublished data show similar numbers 
after intracoronary infusion (Dr. Kyong Hong, Ph.D., Institute of Molecular Cardiology, 
University of Louisville, KY, USA), suggesting that the route of delivery did not affect the 
fate of the cells within the heart. Considering the positive results reported for stem cell 
therapy and the probably lack of cells that form new myocytes based on these studies, it 
appears more likely that it is not cells, but factors released by them that are responsible for 
the improved function seen in clinical trials.6 Therefore, it remains controversial whether 
cells directly participate in cardiac regeneration or whether they are facilitators of the 
regeneration process by releasing paracrine factors. 
b) Although compelling clinical data demonstrate safety of stem cell therapy, 
autologous stem cell transplantation remains a logistic challenge requiring isolation, 
culture, and purification of stem cells suitable for transplantation. In particular, culture and 
purification of different types of stem cells can result in an insufficient number of cells 
suitable for therapy.  
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c) A recent meta-analysis reveals that even with the most commonly used stem cell, 
bone marrow-derived mononuclear cells (BMCs), an average improvement of left 
ventricular (LV) ejection fraction is only 4%7 and with a reduction in infarct size of 4%.8 
Therefore, our laboratory focuses its research on stromal cell-derived factor 1α 
(SDF), one of the factors released from the myocardium or from injected cells after cardiac 
transplantation. Originally thought to play an important role in maintaining the stem cell 
niche microenvironment within the bone marrow (BM), it became clear that SDF by itself 
protects the heart when given prior to myocardial ischemia reperfusion.9 This contribution 
was further supported in studies where cardiac injury was exacerbated when signaling 
through SDF’s receptor CXCR4 was blocked by chronic administration of AMD3100, 
demonstrating an important role of CXCR4 in cardiac homeostasis after myocardial 
infarction.10  
Pre-clinical and clinical studies documented that SDF is up-regulated after 
myocardial infarction,9,11-15 as part of the acute inflammatory response. This induction is 
mediated by hypoxia induced factor-1α (HIF-1α),16 which has also shown to be responsible 
for up-regulation of CXCR4 on progenitor cells, promoting the recruitment of these cells 
towards myocardial injury.17 However, the induction of SDF is transient. It peaks 48 to 72 
hours after myocardial infarction then returning quickly to low baseline levels, reflecting 
its tight control by hypoxic signaling and proteolytic proteins such as elastase, cathepsin 
G, CD26 / dipeptidylpeptidase IV (DPPIV), and metalloproteinases 2 and 9. Therefore, we 
asked whether chronic overexpression of SDF in the heart would accelerate cardiac repair 
beyond the acute inflammatory phase and produce a sustained state of augmented 
regeneration after myocardial infarction.  
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Previous work from our laboratory has shown that SDF down-regulates casein 
kinase 1 alpha (CK1α) in cardiac stem / progenitor cells (CSPC), which played an 
important role in CSPC cell cycle regulation, driving these cells towards a quiescent, non-
dividing state. As CSPCs are potentially important components during cardiac repair, 
factors affecting their ability to regenerate damaged myocardium are crucial components 
to consider. In addition, CK1α is constitutively expressed in many tissues including 
cardiomyocytes, raising the question whether SDF overexpression will also affect 
cardiomyocyte cell cycle through CK1α. 
Therefore, we created a transgenic mouse model in which cardiomyocyte-specific 
overexpression of SDF was induced four weeks before myocardial infarction and 
maintained throughout the entire recovery period, allowing us to not only study the acute 
effect on the heart but also its ability to facilitate cardiac regeneration. 
This dissertation was therefore focused on  
a)  the effect of elevated cardiac SDF on heart, peripheral blood, and 
bone marrow homeostasis,  
b) on its regulation of CK1α as potential important regulator of cardiac 
progenitor and cardiomyocyte cell cycle, and 
 c) on SDF’s potential to regenerate the heart after permanent coronary 
ligation. 
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BACKGROUND AND LITERATURE REVIEW 
Myocardial infarction as a consequence of coronary artery disease remains one of 
the major causes of death. After a critical loss of myocardium in the aftermath of an infarct, 
the remaining myocardium is unable to compensate for the reduced contractile mass 
resulting in increased myocardial stress. Without normalization, this increased myocardial 
stress leads to a progressive decline in function and profound neuroendocrine dysfunction 
ultimately leading to heart failure. There is increasing evidence that stem-cell mobilization 
to the heart and differentiation into cardiac myocytes is a naturally occurring process. 
However, with the potential loss of large areas of myocardium after myocardial infarction 
(MI) the extent of regeneration is too limited and takes place too slowly to be meaningful 
for the recovery of LV function. In a landmark publication, Dr. Pierro Anversa suggests 
that mammalian cardiomyocytes re-enter the cell cycle and subsequently undergo 
karyokinesis and cytokinesis.18,19 However, the number of newly generated 
cardiomyocytes differs significantly from 1.5%20 to 40%21 dependent on the publishing 
group as well as the method used. Despite these differences, it now seems clear that the 
heart maintains its capacity to regenerate, albeit, a very limited capacity. In retaining the 
functionality of stem cells to regenerate damaged myocardium, the therapeutic approach 
for patients with ischemic cardiomyopathy has dramatically changed: Current strategies 
acknowledge the loss of contractile mass and aim to replace the scar tissue with new viable, 
contractile myocardium. The release of factors that act in a paracrine function either 
directly from the injured myocardium or after stem cell therapy might be an important 
determinant of the extent of regeneration. SDF is one of the major factors released by 
injured myocytes after an ischemic insult. It binds to its receptors CXCR4 and CXCR7, 
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which regulate cell homing, survival, proliferation, retention of stem cells in hematopoietic, 
lymphopoietic organs, and tissues affected by inflammation.22 Recent studies suggest that 
SDF also plays a significant role in myocardial ischemia reperfusion9,10 and cardiac 
regeneration. 
CLASSICAL ROLE OF SDF: HOMING FACTOR AND REGULATOR OF BONE 
MARROW HOMEOSTASIS 
Chemokines are chemotactic cytokines that play an essential role in directing 
leukocyte movement during homeostasis, organ development, and inflammatory 
conditions – short, these molecules constitute the host defense against organ damage.23 
More than 50 different chemokines and 20 different chemokine receptors have been cloned 
so far. The CXC chemokine, stromal cell-derived factor 1 (SDF or CXCL12), produced by 
multiple BM stromal cell types and by epithelial cells in many organs,24-29 mediates its 
action through the seven-transmembrane span G-protein coupled receptors CXCR4 and 
CXCR7 expressed on a variety of cell types. Knockouts of CXCR4, CXCR7, or SDF result 
in a diminished colonization of embryonic BM by hematopoietic stem cells and defect in 
the development of the heart, brain, and large vessels.30-35 
As SDF has been shown to play a key role in several functions in homeostasis and 
injury, regulation of its expression and secretion are important. SDF expression has been 
found to be responsive to hypoxia. In a gradient hypoxia model Gurtner and colleagues 
show that SDF secretion increases in endothelial cells by hypoxia and as is a consequence 
of HIF-1α induction.16 Specificity of this action was demonstrated by the presence of HIF-
1α binding sites in the SDF promoter.16 Not surprising, SDF is increased in hypoxic / 
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damaged tissues which serve as a chemoattractant for hematopoietic and other cells 
expressing CXCR4 (i.e. stem / progenitor cells). However, hypoxia can also result in up-
regulation of CXCR4 as its promoter also contains consensus binding sites for HIF-1α, 
suggesting autocrine activation of intracellular signaling pathways.36 
SDF AND CARDIOPROTECTION 
In addition to the long-known properties of SDF in BM homeostasis, recent 
evidence suggests that SDF also plays an important role in cardioprotection and 
regeneration of injured myocardium. Several studies demonstrate SDF1 / XCR4 mediated 
mobilization of BM (BM)-derived stem cells to sides of ischemic injury.12,13,24,37 Hu9 
demonstrated for the first time that ischemic preconditioning resulted in up-regulation of 
SDF in cardiomyocytes but not in fibroblasts and that administration of SDF prior to 
myocardial ischemia / reperfusion injury reduced the infarct size in vivo. SDF 
administration 25 minutes prior to global LV ischemia increases the recovery of the LV 
function after 40 minutes of reperfusion.38 Increased activation by SDF of signal transducer 
and activator of transcription (STAT3) after ischemia reperfusion injury and an abolished 
protection in STAT3 knockout mice suggest that STAT3 contributes to the SDF effect on 
ischemia reperfusion injury.38 Administration of SDF mediated survival in cardiac 
myocytes by activating extracellular regulated kinase (ERK) and AKT as we demonstrated 
in vitro and in vivo.9 Besides the effect on ischemia / reperfusion injury, the importance of 
SDF / CXCR4 during myocardial ischemic injury was elucidated in a permanent coronary 
artery ligation model,10 in which blockade of CXCR4 by chronic administration of 
AMD3100 increased myocardial injury and reduced LV function.10 However, CXCR4 
blockade increased the number of c-kit+ progenitor cells in the area at risk four weeks after 
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myocardial infarction, suggesting regulation of cardiac progenitor / stem cell proliferation 
by SDF / CXCR4. 
For activation of SDF / CXCR4 after myocardial infarction to become a therapeutic 
option the above mentioned limitations (i.e. short half-life, rapid cleavage) need be 
resolved, and different groups tested four different approaches: 
Direct delivery of SDF 
A direct delivery approach was used by Saxena who injected SDF directly into the 
peri-infarct zone of mice that had undergone coronary ligation and found a reduction in 
apoptosis and increased neovascularization.39 To take advantage of both restoration 
strategies (i.e. cell therapy and delivery of SDF), Schuh injected in a rat model endothelial 
progenitor cells and SDF simultaneously into the border zone of the infarct four weeks 
after permanent coronary ligation. This approach increases LV function and increases 
vascularization two months after treatment.40 Finally, Abbott developed a SDF-AdV, 
which was injected into the peri-infarct zone causing a 2.5-fold increase in cardiac SDF 
concentration compared to a control virus 48 hours after injection and resulting in high 
recruitment of mesenchymal stem cells towards the infarct.13 
Transplantation of SDF overexpressing cells 
Several groups used genetically modified cells overexpressing SDF to increase the 
local SDF concentration, using either SDF overexpressing cardiac fibroblasts in 
combination with G-CSF stimulated mobilization of CD117+ and CD34+ cells,12 or 
mesenchymal stem cells transfected with a SDF expression vector.41,42 LV function and 
vascular density in the risk region increase using this approach.  
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Inhibition of proteolytic cleavage of SDF 
To overcome the rapid degradation of SDF, Segers developed a bioengineered 
SDF-fusion protein resistant to MMP2 and CD26 / DPPIV cleavage, which increases 
recruitment of stem cells and improves LV function after intra-myocardial delivery.43 
Zaruba and colleagues followed the same approach by pharmacologically inhibiting 
DPPIV and therefore maintaining a higher SDF level after myocardial infarction. In 
combination with G-CSF44 mediated stem cell mobilization these authors detect an 
increased angiogenesis and a decreased cardiac remodeling resulting in an improved LV 
function. 
Up-regulation of CXCR4 
To increase the recruitment of stem / progenitor cells to the site of injury the last 
approach utilized retroviral-transduced45 or physiologically (i.e. hypoxic preconditioning) 
up-regulated17 CXCR4 expression in mesenchymal- or cardiosphere-derived stem cells to 
accelerate the recruitment to the damaged myocardium. Both approaches result in 
increased recruitment of intravenous transfused cells and increase LV function.  
In summary, most of the above listed studies focused on the chemoattractant 
properties of SDF and aimed to increase the recruitment of different types of stem / 
progenitor cells towards the injury site. 
SDF AS REGULATOR OF CELL CYCLE BY CASEIN KINASE 1 α (CK1α) 
In addition to well known effects of SDF / CXCR4 on cell migration and survival, 
SDF has also been shown to play a role in regulating proliferation of subpopulations of 
hematopoietic progenitors and CSPC. In this side, SDF drives cells to withdraw from the 
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cell cycle at the G0 / G1 interface, resulting in quiescence of these cells.46 In the context of 
stem / progenitor homeostasis, this important mechanism preserves the cell population by 
limiting the number of times these cells divide. Studies in isolated CSPCs demonstrate that 
SDF established a quiescent, non-proliferative state that was dependent on CXCR4.46 
These studies show down-regulation of CK1α, which is well known for its role in 
stablilizing β-catenin, and increase GSK3β activation resulted in an inhibition of cell 
proliferation through cycling D1 and Bmi-1 dependent mechanisms. These data confirmed 
previous work in hematopoietic stem cells, which required SDF or CXCR4 to maintain 
quiescent and provide mechanistic insight into cell cycle regulation. These findings also 
provide a mechanism which helps to explain the longevity of these cells in the BM niche 
to provide a stable stem cell pool. 
PHYSIOLOGICAL ROLE OF CK1α 
 The protein kinase, CK1, has first been described in lactating mammary glands 
which determined the name of the kinase. However, CK1 is a monomeric serine / threonine 
protein kinase responsible for the regulation of several organ functions including 
membrane trafficking, cell cycle progression, chromosome segregation apoptosis, and 
cellular differentiation. Several isoforms (i.e. α, β, γ1, γ2, γ3, δ, and ε)47-52 in addition to 
several splice variants, differing in their kinase activity, have been described.53 CK1α is 
constitutively active but treatment with insulin, viral transformation, and treatment of the 
cell with topoisomerase inhibitors increase the activity.54 Phosphotadylinositol-4, 5-
biphosphate (PIP2) reduces CK1α activity in erythrocytes and neuronal cells and a RNA 
helicase DDX3 regulates CK1.55 Furthermore, CK1 activity is inhibited by auto-
phosphorylation of the c-terminal domain, which serves as a target of cellular phosphatases 
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increasing CK1 activity.56 CK1α has been linked to cell cycle progression, spindle 
dynamics, and chromosome segregation. The studies in Aim II will expand on the previous 
findings in isolated CSPCs and extend our knowledge to include differentiated 
cardiomyocytes. 
STROMAL CELL-DERIVED FACTOR 1 TRANSGENIC MICE / 
GENOTYPING AND BREEDING 
Cardiac specific conditional transgenic mice were generated on the C57BL / mouse 
strain. To temporarily control the SDF overexpression we used a tetracycline (tet) 
transactivator tet-off controlled transgenic mouse line in which myocyte-specific SDF 
overexpression was driven by the α-myosin heavy chain promoter57 (Figure 1). This binary 
inducible transgenic model requiring mice that contain both of the following transgenes:  
(1) A heterologous α-myosin heavy chain (α-MHC)-cardiac-specific promoter 
driving the Tet-controlled trans-activator (tTA) sequence, consisting of a primer of a 
minimal activation domains derived from VP16 (FFF)58 and a rTetR, selected from a yeast 
screen for optimized sensitivity and inductive range, placed into a cardiac-specific α-
myosin heavy chain-specific promoter construct; 
 (2) A full-length α-MHC promoter in which three GATA sites and two tetracycline 
response elements (TRE) were ablated and the remaining cis-acting regions important for 
cardiac-specific expression were left intact. The Tet responsive element consists of seven 





Figure I Characterization of the α-MHC specific -Tet “off” SDF transgenic model  
SDF was overexpressed in double transgenic mice containing a modified (A, left side) α-
MHC driven tetracycline activator gene and an α-MHC modified tetracycline response 
element directing the expression of the SDF1α gene. (A, right side)  
In the presence of doxycycline the transcription of SDF is driven by a minimal promoter 
sequence and “switched off” (B, left side). However, in the absence of doxycycline tTA 
(blue cycle) can bind to the tetO binding site and accelerate SDF expression. 
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This chimeric promoter is ligated to the SDF gene, which is then conditionally 
controlled: In the presence of tetracycline or its analogue doxycycline, the transcription of 
SDF is only driven by the very low basal activity of the minimal promoter and “switched 
off” while in its absence tTA can bind to the TetO, allowing the VP16 transactivator to 
increase the expression of SDF, driven by the heterologous α-MHC promoter, and therefore 
“switched on”. The tet-off model allowed us to determine the time of gene overexpression, 
and we removed doxycycline from the drinking water at eight weeks of age when mice 
become adolescent. We detected increased gene-overexpression three weeks after 
doxycycline withdrawal determined by PCR and western blot analysis (Figure 2), and 




Figure II Myocardial SDF concentration before and after activation of the transgene 
Myocardial SDF concentration in wild-type (WT) and in “low” (SDF low) and “high” 
(SDF high) expressing transgenic mice. Mice were euthanized while receiving 
doxycycline (“on dox”) and three weeks after induction of cardiomyocyte-specific SDF 




















Assuming a Mendelian pattern of inheritance, one in four offspring would carry 
both transgenes. We used exclusively male mice for the ligation experiments to avoid any 
estrogen cycle dependent impact on the size of injury. Therefore, 12.5% of all offspring 
mice were available for ligation experiments (Table 1), resulting in a total of 725 mice 















Myocardial infarction is a prevalent consequence of cardiovascular disease (CVD) 
contributing to one in four deaths in the US. Unfortunately, there is no therapy to reverse 
effects of lost myocardium due to myocardial infarction, only therapies to deal with the 
consequences. Although stem cell therapy seems to be promising to regenerate damaged 
myocardium, current approaches lack efficiency. It is essential that a better understanding 
of mechanisms associated with regeneration is obtained and then utilized to develop more 
effective therapeutic approaches to alleviate the significant burden of CVD and improve 
patient quality of life.  
PROPOSED EXPERIMENTS  
This thesis will evaluate the effect of chronic SDF overexpression on cardiac 
regeneration after permanent coronary ligation. In particular, we will focus on the effect of 
SDF on the myocardium and its regeneration potential and how BM homeostasis is 
affected. One of the key challenges in the proposed studies will be to demonstrate changes 
in infarct size that are a consequence of myocardial regeneration. We will use two indices 
to assess infarct size, scar size, and viable myocardium and accompany these with 
immunofluorescent detection of new myocytes by BrdU incorporation. We will further 
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evaluate whether CK1α plays an important role in cardiac regeneration and whether it 
serves as a mediator of SDF induced cardiac regeneration. 
HYPOTHESIS 
Cardiomyocyte-specific overexpression of SDF accelerates cardiac regeneration 
after permanent coronary ligation by increasing CK1α mediated cardiomyocyte division. 
SPECIFIC AIMS  
I) To determine the effect of chronic cardiomyocyte-specific overexpression of 
SDF on cardiac and bone marrow homeostasis. 
II) To determine whether casein kinase 1α mediates cardiac stem / progenitor cells 
and neonatal cardiomyocyte proliferation. 
III) To determine whether cardiomyocyte-specific overexpression of SDF increases 






AIM I – TO DETERMINE THE EFFECT OF CHRONIC 
CARDIOMYOCYTE-SPECIFIC OVEREXPRESSION OF SDF ON 
CARDIAC AND BONE MARROW HOMEOSTASIS
BRIEF PREVIEW 
Background  
The proposed studies focus on changes in the heart (i.e. cardiomyocytes) and in the 
BM as a major source of progenitor cells. As a chemoattractant, BM derived SDF helps to 
retain diverse population of hematopoietic precursors including CD34+ stem / progenitor 
cells (HSCs / HPCs) in the BM and serves as an “anchor” for leukocytes within the BM 
niche. Stressors or injury that alter the homeostatic influence of SDF would impact this 
balance leading to decreased retention and mobilization of these cells, leading to increased 
circulating levels. Therefore, we asked whether an “imbalance” due to myocardial 
overexpression of SDF would shift the homing preference of circulating HSPCs / 
endothelial progenitor cells (EPCs) towards the heart and subsequently affect the 
circulating stem cell pool. SDF / CXCR4 interaction promotes neovascularization in 
different types of tissue injury by recruiting endothelial progenitor cells.59,60 For that 
reason, we measured the number of leukocytes in the peripheral blood and endothelial 
progenitor cells (EPCs, Sca-1+ / Flk-1+ cells) in the peripheral blood and the BM. 
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Since recently published data demonstrates that SDF regulates the cardiac stem / 
progenitor cells’ (CSPC, c-kit+ cells) cell cycle through CK1α46, we also determined the 
expression of cardiac CK1α and the number of CSPCs in WT and SDF transgenic (Tg) 
mice. Previously we demonstrated that SDF administration was associated with an increase 
in ERK and AKT.9 Therefore, we determined AKT under baseline condition in WT and 
SDF overexpressing mice. 
Methods 
Two lines of cardiomyocyte-specific SDF Tg mice expressing “low” (SDF low) 
and “high” (SDF high) levels of SDF were used in the described studies. Cardiac SDF 
levels were determined by ELISA before and three weeks after activation of the transgene 
in “high” and “low” SDF overexpressing mice. Protein levels of CK1α and AKT were 
determined by western blot analyses using standard protocols. The number of leukocytes 
was determined by an automatic hematology analyzer five and 30 weeks after initiation of 
cardiac SDF overexpression and the number of circulating EPCs detected by FACS 
analysis. 
Results 
Interestingly, the number of leukocytes decreased in the peripheral blood five and 
30 weeks after the removal of doxycycline from the drinking water and induction of SDF 
overexpression in the heart while there was no change in the number of platelets and red 
blood cells in the peripheral blood. To verify this unexpected result we performed a second 
set of experiments to determine the time course of these hematological changes, confirming 
lower numbers of leukocytes in the peripheral blood of SDF Tg mice compared to WT 
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mice. The number of EPCs was lower in SDF Tg mice in the BM and the peripheral blood. 
While we saw an increase in EPCs 72 hours after permanent coronary ligation in SDF Tg 
mice, numbers in WT mice remained unchanged. 
Overexpression of SDF resulted in a concentration dependent increase of cardiac 
CK1α and phosphorylation of AKT and an increase in CSPCs determined by 
immunopathology. Interestingly, BrdU staining indicated a reduced number of dividing 
CSPCs.  
Conclusion 
Although SDF overexpression was cardiomyocyte-specific, the level of SDF was 
sufficient to affect the periphery and reduce circulating leukocytes and diminish the 
number of EPCs in the peripheral blood and the BM. CK1α increased in SDF 
overexpressing mice, affecting proliferation of CSPCs. 
MATERIAL AND METHODS 
Animals 
SDF Tg mice were bred, maintained, and used in described studies at the University 
of Louisville under protocols approved by the Animal Care and Use Committee and 
adhered strictly with the Guide for the Care and Use of Laboratory Animals (NIH 
Publication No. 86-23, Revised 1996). For the proposed experiments in Aim I female mice 
were used from SDF Tg lines overexpressing low and high SDF concentrations (as outlined 
above) and their WT littermates served as age matched controls. A diurnal 12 hour day / 
night cycle was maintained. At the age of eight weeks, removal of doxycycline from the 
drinking water successfully induced SDF overexpression (Figure 2). A second set of 
 20 
experiments was performed in elderly mice (60 weeks of age) to determine the effect of 
chronic SDF overexpression (i.e. at least 30 weeks) on the number of circulating 
leukocytes. 
Hematology 
Two sets of experiments were performed to establish the effect of SDF on 
hematopoiesis: In a first set of experiments, blood samples were taken from mice of 
different ages (15 and 60 weeks old) and the number of leukocytes (WBCs), red blood cells 
(RBCs) and platelets was determined. In a second set of experiments, we established a five-
week time-course of individual changes in WBC, RBC, and platelet numbers in the 
peripheral blood before and after the removal of doxycycline from the drinking water. 
Blood samples were taken at time “0” (eight week old mice receiving doxycycline) and 
eight, 16, 24, and 32 days after doxycycline removal. Blood was collected by puncturing 
the retrobulbar plexus and collecting ~150 µl of blood into a microvette EDTA coated tube 
(Sarstedt Inc., Newton, NC, USA) stored on ice. The daytime of the blood collection was 
kept constant throughout the entire experimental period to avoid circadian changes in cell 
numbers. The corpuscular blood composition was determined within 30 minutes using an 
automatic hematology analyzer (Cell DYN 3500, Abbott Diagnostics, Princeton, NJ, 
USA). 
Flow cytometry / FACS analysis 
The number of circulating and resident BM EPCs was determined from whole 
blood samples collected, as described above. After automatic cell counting the samples 
were treated with an erythrocyte lysis buffer (Roche) for one minute at room temperature. 
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Samples were then washed twice to remove the cell debris and transferred to a staining 
buffer (PBS supplemented with 5% fetal bovine serum (FBS), 1% bovine serum albumin 
(BSA)). Cells were stained 45 minutes in the dark for stem cell antigen (Sca-1, Antibody, 
FITC conjugated) as a hematopoietic stem cell marker and for fetal liver kinase 1 (Flk-1, 
APC Rat anti-mouse, BD Pharmingen), the receptor for vascular endothelial growth factor 
as an endothelial cell marker. After two subsequent washing steps, FACS analysis was 
performed (Accuri C6, Becton Dickinson Bioscience, San José, CA, USA). 
Bone marrow collection 
Mice were euthanized by CO2 inhalation followed by cervical dislocation, then both 
femurs were removed and placed in sterile phosphate buffered saline (PBS) solution. Soft 
tissue was removed from the bone with a fine forceps to avoid the contamination of the 
BM sample. The bone shaft was then flushed with PBS using a 23-gauge needle and a ten 
milliliter syringe. Cells were further dissociated by careful repeated passage of the flushed 
BM through the 23-gauge needle. The cell suspension was filtered through a 70-µm nylon 
mesh filter to remove clumps, counted with a hemocytometer and then transferred to a 
FACS staining buffer for further processing, as described above. 
Coronary ligation 
All animal procedures were approved by the University of Louisville IACUC in 
accordance with the NIH Guide for the Care and Use of Laboratory Animals (DHHS 
publication No. [NIH] 85-23, rev. 1996). After inhalational induction of anesthesia (3-5 
Vol.% Isoflurane (Abbott Laboratories, Abbott Park, IL, USA) in an induction chamber, 
the trachea was intubated with a 22-gauge intravenous catheter. The successful intubation 
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was verified by bilateral chest movement after connection to a small rodent ventilator 
(Harvard Apparatus, Holliston, MA, USA). The lung was volume controlled ventilated at 
a rate of 150-200 strokes / minute and a tidal volume of 200 µl. Having shaved the chest 
with an electric razor, the mice were placed on an adjustable temperature (TCAT-2LV 
controller, Physiotemp, Clifton, NJ, USA) heating pad with a 37°C setup. All procedures 
were performed under a surgical microscope (MZ95, Leica Microsystems, Buffalo Grove, 
IL USA), using a sterile surgical technique. After opening the thoracic cavity between the 
fourth intercostal space and dissection of the pericardium, the left descending coronary 
artery was identified and subsequently ligated by a single stich ligation with an 8.0 suture 
(Nylon, AA-0145, Surgical Specialties Corp, Vancouver, BC, Canada) about 2-3 mm 
below the aortic root. The successful ligation was confirmed by epicardial cyanosis and 
bulging of the myocardium during systole. The chest was subsequently closed in layers, 
using a 5.0 Vicryl suture (PC-1, 1855G, Ethicon, Cincinnati, OH, USA). After extubation 
the mice recovered for 30 minutes to one hour in an oxygen chamber (FiO2=0.8) before 
they returned to an animal cage, being placed on a heading pad overnight. 
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Confocal microscopy 
One limitation of conventional microscopy for achieving high-resolution images is 
based on the physical properties of the emitted light: 
 
 
Figure III Confocal microscopy scheme 
A microscope objective is used to focus a laser beam onto the specimen, where it excites 
fluorescence. The fluorescent radiation is collected by the objective and efficiently 
directed onto the detector via a dichroic beamsplitter. The interesting wavelength range of 
the fluorescence spectrum is selected by an emission filter, which also acts as a barrier 
blocking the excitation laser line. The pinhole is arranged in front of the detector on a 
plane conjugate to the focal plane of the objective. Light coming from planes above or 
below the focal plane is out of focus when it hits the pinhole, so most of it cannot pass the 
pinhole and therefore does not contribute to forming the image (Copyright Carl Zeiss, 
Jena, Germany). 
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In thick tissue sections, like the myocardium, the focus area is always greater than 
the wave-optical depth of the specific sample. Therefore, the in-focus information of the 
image is mixed with surrounding out of focus image information, reducing the contrast of 
the image. Using multiple fluorescence dyes result in a mixture of signals into different 
color channels, limiting conclusions about co-localization of the labeled structures. In 
contrast, confocal imaging uses an optical aperture, which only collects data within the 
focal plane while rejecting outside reflections from the sample. Using LASER (Light 
Amplification by Stimulated Emission of Radiation) light featuring a high spatial and 
temporal coherence, confocal microscopes are capable of scanning tissue samples with a 
single color (wavelength) and a high spatial resolution. In addition, sample images can be 
acquired in a single plane (i.e. slice), which result in a stack of images when moved along 
the z-axis in defined increments, allowing to assemble a 3-dimensional reflection of the 
specimen. (Figure 3). The Zeiss LSM510 confocal microscope (Carl Zeiss, Jena, 
Germany) is equipped with three different LASER types: An Argon / Krypton laser 
(emitting wavelength: 458 / 488 / 514 nm), an UV laser (405 nm), and a Helium laser (633 
nm). The laser light is directed towards a dichroic mirror through a specific objective onto 
the specimen where specific fluorophores are excited and subsequently emit light of a 
different wavelength back towards a dichroic beamsplitter, which allows the passage of 
light of a define wavelength towards a detector via a precisely aligned pinhole. In our 
experiments, we used up to four different fluorophores to identify and detect co-











495 519 Green 
Tetramethylrhodamine 
(TRITC) 
547 572 Red 
Cyan (Cy5) 649 670 Cyan 
4’,6-diamidino-2-phenylindole 
(DAPI), nuclear stain 
345 455 Blue 
 
Preparation for pathological specimens 
At the end of each recovery period (i.e. one or four weeks), the mice were re-
anesthetized, and the heart was arrested in diastole by injecting a filtered saturated KCl (3 
M) and cadmium (Cd, 0.1 M, Sigma Aldrich, St. Louis, MO, USA) solution through the 
apex into the LV cavity. Thereafter, the aorta was cannulated, and the heart retrograde 
perfused at a rate of 0.5-1 ml / minute with 37°C warm PBS. After five to ten minutes and 
complete blood removal, the perfusion was switched to 10% buffered formalin solution. 
The solution was infused under constant pressure (80 mmHg) for an additional 10-15 
minutes. The LV cavity pressure during the fixation period was kept constant at 13 mmHg 
by infusing formalin through a 26-gauge needle inserted into the cavity through the LV 
apex. After subsequent fixation in 10% buffered formalin for up to seven days atrial 
appendices were removed, hearts were weighted and cut into two millimeter thick cross-
sectional slices in a mouse heart tissue slicer (Zivic Instruments, Pittsburgh, PA, USA). 
Table 2 Fluorophores used for detection of different antigens by confocal 
microscopy  
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After tissue processing for paraffin embedding (Tissue-Tek VIP, Miles Scientific), tissue 
samples were cut (rotary microtome RM2155, Leica Microsystems, Buffalo Grove, IL, 
USA) into four micrometer thick sections for histological and immunofluorescent staining. 
Sections were stored at 4°C until their final usage. Prior to histological staining, sections 
were de-paraffinized and rehydrated to distilled water using a standard graded xylene-
ethanol series. 
Immunofluorescence staining 
Formalin containing fixatives cause cross-linking of proteins and mask antigen sites 
in tissue sections, making those unavailable for detection by antibodies. Therefore, we used 
a basic EDTA buffer (pH 8.0) in which tissue sections were boiled for 15 minutes in a 
microwave oven, followed by a 30 minutes cool-down period. Thereafter, sections were 
equilibrated in TN buffer (0.1 M Tris-HCl, 0.15 M NaCl, 0.05% Tween 20) for five 
minutes, followed by quenching of endogenous peroxidase with 3% H2O2 for 10 minutes 
at room temperature. After threefold washing in TN buffer, sections were blocked with TB 
buffer containing 0.5% blocking agent (FP1020, PerkinElmer Inc., Waltham, MS, USA) 
and subsequently incubated overnight with a c-kit antibody (1:100, mouse stem cell factor 
receptor / c-kit, AF1356, R&D systems, Minneapolis, MN, USA). To develop the final 
signal, sections were incubated with bovine anti-goat horseradish peroxidase (HRP) 
antibody (1:200, Cat.# 805-035-180, Jackson Immunoresearch, West Grove, PA, USA) for 
one hour at room temperature followed by five washing steps and four minutes incubation 
in amplification working buffer (1:50 diluted TRITC fluorophore in amplification buffer, 
TSA Plus TMR kit, PerkinElmer, Inc.). To exclude hematopoietic, c-kit+ cells from our 
analysis, sections were incubated with a CD45 antibody (CD 45, 1:50 in 1% BSA and 10% 
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donkey serum, cat.# 610265, BD transduction Laboratories) for 30 minutes at 37°C and 
then stained with a donkey-anti-mouse IgG FITC conjugated secondary antibody 1:100, 
Cat.# 715-095-151, Jackson Immunoresearch, West Grove, PA, USA). Finally, a 15 
minutes incubation in a DAPI solution [1:1000 in Dulbecco's PBS (DPBS)] marked the 
nuclei. Prior to mounting cover glasses, tissue auto-fluorescence was blocked by a 30 
minutes incubation in Sudan black B solution (Cat# 199664, 1 mg / ml in 70% ethanol, 
Sigma Aldrich, St. Louis, MO, USA,). CSPC proliferation was determined in a second set 
of tissue sections, measuring BrdU incorporation (see page 52). After c-kit staining, these 
sections were incubated with an anti-BrdU primary antibody (1:50, clone BMG 6H8 IgG) 
for two hours at 37°C, washed five times for six minutes in DPBS, and stained with a FITC 
conjugated secondary anti-mouse IgG antibody (5-Bromo-2’deoxy-uridine labeling and 
detection kit I, Roche Diagnostics GmbH, Mannheim, Germany). 
Western blot analysis 
The mice were euthanized as previously described, and their hearts were quickly 
removed and washed in ice-cold PBS. Half of the tissue was used for western blot analysis 
performed as previously described.9 Briefly, the tissue was immediately homogenized in 
lysis buffer containing (in mmol / L): 25 Tris-HCl, pH 7.5, 100 NaCl, 0.5 EDTA, 0.5 
EGTA, 1% phosphatase inhibitor cocktail 2 (P5726, Sigma Aldrich), 1% phosphatase 
inhibitor 3 (P0044, Sigma Aldrich), 0.1% Triton X100, and 2% protease inhibitor cocktail 
(P8340, Sigma Aldrich). Thereafter, the tissue homogenate was cleared by centrifugation 
at 14,000 x g for ten minutes, followed by determination of the protein concentration in the 
supernatant (Biorad Protein Assay, Bio-rad, Hercules, CA, USA). Sample aliquots were 
stored at -80°C until used or were denaturated for three minutes at 95°C for immediate 
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usage. Gels for SDF PAGE were loaded with equal amounts of protein per lane, followed 
by a transfer to the Hybond ECL membrane (GE Healthcare Life Science, Piscataway, NJ, 
USA). After overnight incubation with primary antibodies at 4°C, proteins were detected 
with HRP-conjugated anti-mouse or anti-rabbit antibodies (1: 10000, Cell Signaling 
Technology, Beverly, MA, USA) and the ECL plus chemiluminescent detection system 
(GE Healthcare Life Science, Pittsburgh, PA, USA).  
The following primary antibodies were used: CK1α (Cell signaling, 1:1000), AKT 
(Cell signaling, 1:1000), phosphor-AKT (Cell signaling, 1:1000), and GAPDH (Cell 
signaling, 1:1000). Densitometry analysis was performed using a Typhoon scanner (GE 
Healthcare Life Science, Pittsburgh, PA, USA). 
SDF ELISA 
Tissue homogenates of “high” and “low” SDF overexpressing mice were collected 
before and three weeks after induction of the transgene. Samples were prepared as 
described above and further handled according to the manufacturer’s recommendation 
(Cat. No. McX120, mouse CXCL12 / SDF-1α immunoassay, RD systems). Optical density 
was measured at 450 nm with a wavelength correction at 570 nm. Results were calculated 
from a standard curve generated by dilutions of known amount of recombinant SDF 
protein, as previously described.9 Levels of SDF were normalized to total protein and 
expressed in pg / 100 ug protein (mean±SEM). 
Statistical Analysis 
All data are expressed as mean±SEM. Differences were analyzed using unpaired 
Student’s t-test or two-way ANOVA [group effect (i.e. genotype) and time effect (time 
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after initiating SDF overexpression)] with Bonferroni’s correction for multiple 
comparisons. The statistical significance was defined as P<0.05 or in case of multiple 
comparisons adjusted by dividing 0.05 by the number of comparisons. The statistical 
analyses were performed using PRISM software (Vers. 6.0e for MAC OSX, Graphpad 
Software, La Jolla, CA, USA). 
RESULTS 
Cardiac specific overexpression of SDF decreases leukocytes in the peripheral blood and 
the BM. 
Blood samples from mice overexpressing cardiac SDF for five or 30 weeks, 
respectively, revealed a reduction in WBCs after five weeks (WT: 9.8±1.3 x 103 / ml vs. 
SDF: 6.2±0.7 x 103 / ml, P<0.05) while the number of RBCs and platelets did not change 
(Figure 4). In contrast, all three lineages of hematopoiesis (i.e. erythropoiesis, 
lymphopoesis and myelopoiesis) were depressed after long- term overexpression of SDF 
in the peripheral blood (WBCs, WT: 5.8±0.7 x 103 / ml vs. SDF high: 3.9±0.5 x 103 / ml, 
P=0.08; RBCs, WT: 8.9±0.3 x 103 / ml vs. SDF high: 8±0.3 x 103 / ml, P<0.05; platelets, 
WT: 1147±62 x 103 / ml vs. SDF high: 900±109 x 103 / ml, P=0.05). Serial experiments 
with repeated blood collection per mouse confirmed the WBC data. Although the data did 
not reach statistical significance at a specific time point, the two-way ANOVA indicated 
significant influence of genotype and time on WBC numbers with a reduction in WBC in 
the SDF Tg mice. (Figure 5). Interestingly, we did not find any difference in RBC and 




Figure IV WBCs, platelets and RBCs in the peripheral blood after five and 30 weeks 
of cardiomyocyte-specific SDF overexpression 
Barplot represents data from WT (n=7) and high expressing (SDF high) transgenic mice 
5 weeks (left side) and 30 weeks (right side) after initiating transgene expression. SDF 
overexpression depressed WBCs counts at both time points while the number of RBCs 
was only diminished in the elderly mice. Interestingly, platelet count was initially higher 
in the transgenic mouse, but became depressed after 30 weeks of SDF expression. 
Samples were taken at a single time point. Comparisons are done as unpaired t-test, 
*P<0.05. 
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The changes in hematopoiesis were further investigated, and we measured the 
number of EPCs in the BM and peripheral blood. SDF overexpression resulted in a trend 
towards decreased circulating and BM resident EPCs under baseline conditions compared 
to that in WT mice (Figure 6). The number of EPCs almost doubled in the peripheral blood 
72 hours after permanent coronary ligation with no change in numbers in the BM, 
demonstrating a reversal of impact of MI on mobilization of EPCs. However, based on the 
limited number of experiments (n=3) we did not reach statistical significance limiting the 




Figure V Time course of hematological changes after initation of SDF expression in 
WT and SDF high transgenic mice 
Doxycycline was removed from the drinking water and blood samples were subsequently 












































Figure VI Bone marrow resident and circulating EPCs in WT and Tg high mice 
14 weeks old mice underwent sham operation or permanent coronary ligation. Blood and 
BM samples were collected 72 hours later. Samples were stained for Sca-1 and Flk-1 and 
measured by FACS analysis.  
Bone marrow
Peripheral blood
Sca+/Flk+ cells x 10-4 events
Sca-1+/Flk+ cells/ ml
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Cardiomyocyte-specific overexpression of SDF increases gene-copy dependent CK1α 
expression and AKT phosphorylation in the heart.  
We determined the expression of CK1α in whole heart homogenates and found that 
CK1α was gene-copy number dependent increased. (Figure 7 right side). Similarly, total 
AKT increased parallel to the SDF expression level in the heart, while phosphorylation of 
AKT did not change. (Figure 7 left side). 
 
 
Figure VII Gene-copy dependent protein expression of AKT and CK1α 
SDF overexpression resulted in gene-copy dependent increase in total AKT (left panel) 
while pAKT was unchanged. SDF overexpression increases CK1α expression gene-dose 
dependent. Total heart protein was collected five weeks after initiation of SDF 
overexpression. The data represent two independent experiments demonstrating similar 
results.  
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Cardiomyocyte-specific overexpression of SDF resulted in an increased number of c-kit+-
cells.  
Sections of sham-operated WT and SDF high mice were stained for the stem cell 
factor receptor c-kit. The number of c-kit+ positive cells in the LV wall was higher in SDF 
overexpressing mice four weeks after sham operation, while the number of c-kit+ / BrdU+ 
cells was similar to WT mice. Interestingly, the proportion of c-kit+ cells which were BrdU+ 
was lower in SDF high hearts (one third) than in WT mice (one half). With the current 
number of experiments, these differences were not statistical significant, but might indicate 




Figure VIII c-kit+ cell in WT and SDF high expressing transgenic mice  
The upper panel presents an example of a c-kit+ CSPC, while the lower panel presents on 
the left side the total number of c-kit+ cells and the right side the number of BrdU+ /  kit+ 
cells. With the current number of experiments, there was no statistical significance 
between WT and SDF high mice.  
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CONCLUSION 
Our data indicate for the first time, that chronic cardiomyocyte-specific SDF 
overexpression affects BM derived hematopoiesis as we found a reduction in circulating 
leukocytes accompanied lower, but not statistical significant, numbers of EPCs both in the 
peripheral blood and the BM. These results are surprising, considering a relatively short 
half-life of SDF when released into the peripheral blood. CD2661,62, and serum proteases63 
quickly cleave SDF, which is reflected by failure to detect SDF in the serum of “high” level 
SDF expressing mice (data not shown). In fact, others also failed to detect SDF in the blood 
plasma64 in a model using a RSV-promoter to drive SDF expression in all or most tissues, 
presumably reaching higher SDF levels than in our model. However, the authors describe 
an enhanced progenitor cell cycling, resulting in higher absolute numbers of CFU-GM, 
BFU-E, and CFU-GEMM in the spleen, and to a lesser extent in the BM, where SDF 
significantly increase GM-CSF-responsive CFU-GM and M-CSF-responsive CFU-M.64 
These data stand in contrast to our findings as we rather see a decrease in leukocytes.  
Our data are limited considering the total number of experiments and animals 
included taking the variation in WBC numbers into account, even under physiological 
conditions. The lower number of leukocytes and EPCs in the peripheral blood can be 
interpreted as a change in homeostatic equilibrium between the BM and the periphery, 
which would diminish the ability of the BM to participate as cell source in a cardiac 
regeneration process. 
SDF overexpression leads to an increase in CK1α. CK1α has been suggested to be 
constitutively active, widely expressed and without significant regulation.53 Data from our 
laboratory suggest that the SDF-mediated decrease in CK1α decreases CSPCs cell 
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proliferation.46 According to this concept we found less c-kit+ / BrdU+ cells in SDF high 
mice compared to WT mice, suggesting a more quiescent status of CSPC.  
In combination with the increased phosphorylation of AKT known to provide a 
powerful survival signal for the heart, we conclude that cardiac overexpression of SDF 
might provide a cardioprotective phenotype, including an increase pool of non-cycling 
CSPCs. 
The implications of our data are limited based on the small number of experiments 
and the lack of statistical significance. Therefore, these data should be interpreted with 






AIM II – TO DETERMINE WHETHER CASEIN KINASE 1Α MEDIATES 




Although SDF induces quiescence in hematopoietic progenitors and stem cells,65,66 
SDF has been shown to increase proliferation under specific experimental conditions. In 
the presence of thrombopoietin, SDF induces megakaryocyte progenitor cells (CFU-MK) 
proliferation67 and in human circulating CD34+ / CXCR4+ cells, 48 hour incubation with 
SDF increased the percentage of cells in S / G2 / M phases compared to untreated controls.68 
The later effect was augmented in the presence of cytokines.68 Previous data from our 
group suggested that SDF facilitates CSPCs quiescence by blocking cell cycle progression 
at the G0 to G1 transition.46 In CSPCs, we showed that SDF decreased the expression of 
CK1α, a protein kinase considered constitutively active in multiple tissues and to this point 
without any known regulation. The gene dose dependent increase in CK1 expression in the 
SDF Tg hearts was in contrast to that seen in CSPCs. To determine whether increased 
CK1α expression in CSPCs and cardiac myocytes increased proliferation CK1α was 
overexpressed and proliferation measured in vitro. 
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Methods  
The effect of CK1α overexpression on un-differentiated and differentiated cells was 
determined in human CSPCs [kindly provided by Dr. Roberto Bolli, M.D. (Institute of 
Molecular Cardiology, University of Louisville)] and cultured rat neonatal 
cardiomyocytes, respectively. Cells were cultured and transfected with pCMV-CK1α. 
CK1α protein expression was measured 48 hours later with western analysis. Control 
treated cells were transfected with the equivalent of pCMV-mCherry. Cell proliferation 
was determined by measuring BrdU incorporation 48 hours after labeling in BrdU 
containing medium. 
Results 
Transfection of human CSPCs and neonatal rat cardiomyocytes with pCMV-CK1α 
resulted in increased expression of CK1α that was dependent on the amount of input vector. 
Importantly, increased CK1α expression correlated with increased proliferation in both 
human CSPCs and myocytes, and proliferation increased with increasing CK1α 
expression. 
Conclusion 
These experiments indicated that the cell cycle was regulated by CK1α. Previous 
data suggested that SDF regulates CSPCs cell cycle through down-regulation of CK1α. 
The current experiments provided evidence that up-regulation of CK1α caused the reverse 
effect and accelerated cell proliferation in un-differentiated and differentiated cells. 
Therefore, our data established CK1α as an important regulator of cardiomyocyte cell cycle 
and its up-regulation after myocardial infarction would accelerate cardiac regeneration. 
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MATERIAL AND METHODS 
Isolation of human cardiac stem / progenitor cells 
Human cardiac stem cells were isolated during the SCIPIO trial and stored in liquid 
nitrogen until used. For our experiments cells were thawed, plated, and cultured in 
supplemented stem cell medium containing (DMEM / F12, LIF, ITS, bFGF, Glutamine) 
up to 4 passages in T75 flasks. An adequate purity of the cell culture was achieved when 
FACS analysis indicated more than 80% c-kit+ cells in the cell preparation. 
Isolation of neonatal cardiomyocytes 
Neonatal cardiomyocytes were obtained from Sprague-Dawley rats on the day of 
birth and about 10 pups were used for each cardiomyocyte preparation. After cleaning the 
rat with 70% ethanol, a quick decapitation was performed and the thorax was opened with 
scissors. The hearts were removed and quickly placed in calcium- and bicarbonate-free 
Hanks with Hepes buffer containing in mM (138 NaCl, 5.8 KCl, 0.8 Mg, 0.8 PO4, 5.5 
Dextrose, 20.06 HEPES, pH 7.4) and heparin (0.15 ml) for subsequent dissection. After 
incubation in trypsin and DNAse for 20 minutes, the tissue was slowly further dissected 
towards a single cell suspension. Cells were then transferred to MEM Eagles with Hanks 
containing penicillin, B12 and 5% calf serum medium, filtered through a cell strainer, and 
pre-plated for 30 minutes at 37°C to remove non-myocytes. Cells from the supernatant 
were then plated in 96 well plates in MEM Eagles with Hanks containing B12, 5% calf 
serum and BrdU (0.1 mM) for 48 hours. 
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Transfection of neonatal cardiomyocytes and human CSPCs with CK1α containing 
plasmid 
Human CSPCs and neonatal cardiomyocytes (2 x 104 cells / well) were transferred 
to 96 well plates and transfected using a cationic liposome formulation (Lipofectamine 
2000 with plus reagent, Invitrogen / LifeTechnologies, Grand Island, NY, USA) and 0.5 
µL lipofectamine LTX reagent to transfect cells with different plasmid DNA 
concentrations (i.e 0.25, 0.5, 0.75, 1.0, 1.5, and 2.0 µg / µl). CK1α protein expression was 
measured after 48 hours by western blot analysis. 
Measurement of cell proliferation 
The cell proliferation was measured using a commercially available BrdU detection 
kit (Calbiochem, QIA 58). The transfected cells were cultured in BrdU (1:2000) containing 
opti-Mem medium for 48 hours, and the extent of BrdU incorporation was reflected by the 
intensity of the absorbance in a final staining reaction: After 48 hours the cells were fixed 
and the DNA denaturated. After adding anti-BrdU antibody (1:100), the cells were 
incubated for one hour at room temperature. After a subsequent washing step a secondary 
HRP-conjugated antibody was added and incubated for 30 minutes at room temperature. 
The plates were washed again and 200 µL of substrate added to each well. After a 15 
minute incubation in the dark stop solution was added. The supernatant of each well was 
transferred to a different 96 well plate, and the absorbance measured by platereader 
(Synergy 4, Biotek, Winooski, VT, USA) at dual wavelengths (450 nm and 595 nm). 
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RESULTS 
CK1α induces proliferation of human CSPCs 
After 48 hours of incubation, western blot analysis revealed a concentration 
dependent increase in CK1α expression in transfected CSPCs. CK1α also increased 
concentration dependent BrdU incorporation indicating accelerated proliferation after 
administration of CK1α (Figure 9A). 
CK1α induces neonatal cardiomyocyte proliferation 
The western blot analysis of protein samples from neonatal cardiomyocytes 
harvested 48 hours after transfection revealed a similar increase (data not shown) as seen 
in CSPCs. Furthermore, we detected a concentration dependent augmentation of BrdU 




The cellular function of CK1α is not well understood. Here we provide evidence 
that CK1α facilitates concentration dependent cell proliferation in human CSPCs and in 
                       
 
Figure IX Proliferation of human CSPC and neonatal rat cardiomyocytes after 
transfection with CMV-CK1α vector 
9A: Proliferation of human CSPCs and 9B, proliferation of rat neonatal cardiomyocytes. 






neonatal cardiomyocytes. These data confirmed our previous finding46 and suggested 
CK1α as a novel regulator of cell cycle in the CSPCs and cardiomyocytes.   
The presented data reflect the results of two independent experiments in two 
different kind of tissues (human CSPCs and rat neonatal cardiomyocytes) suggesting the 
same effect of CK1α. Despite the lack of statistical significance caused by the limited 






AIM III – TO DETERMINE WHETHER CARDIOMYOCYTE-SPECIFIC 
OVEREXPRESSION OF STROMAL CELL-DERIVED FACTOR 1 




In addition to other investigators, our group has previously shown that SDF, given 
before myocardial ischemia / reperfusion, protected the heart in a preconditioning-like 
manner9 and that blockade of CXCR4 by AMD3100 accelerated myocardial injury.10 
Several previous studies have shown that increasing SDF in the heart by either preventing 
protease mediated cleavage43,69 or increasing SDF concentration through transplantation 
transfected fibroblasts12 or SDF overexpressing mesenchymal stem cells13 improves 
myocardial function. Whether SDF facilitated myocardial regeneration was not assessed in 
any of these models. 
Methods 
The regeneration potential in SDF and WT mice was evaluated at different time 
points after permanent coronary ligation. The earliest infarct size measurement was 
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performed three days after permanent coronary ligation to ensure an equivalent degree of 
injury between the mouse strains. At this early time point, we stained hearts with 
triphenyltetrazolium chloride (TTC) to determine the infarct size. Subsequently, we 
sacrificed mice after seven and 30 days to assess the LV remodeling process. At these time 
points, Masson’s trichrome staining was utilized for infarct size assessment. During the 
recovery period, mice received 5-bromo-2 deoxycytidine (BrdC) allowing us to determine 
the amount of proliferation within the myocardium through detection of incorporated BrdU 
derived from BrdC. These data were verified by Ki67 staining, a marker of cell mitosis, 
reflecting the amount of cells undergoing cell division at the point of sacrifice. In addition 
to the regenerative aspect of remodeling, we determined the apoptosis rate by 
deoxynucleotidyl-transferase-mediated dUTP nick end-labeling (TUNEL) staining. 
Furthermore, we determined the capillary density in the border zone and the remote area 
as indicators of neovascularization. Staining for the stem cell factor receptor c-kit 
determined the number of CSPCs. 
To verify the long-term effect of SDF overexpression on cardiac remodeling, 
elderly mice underwent the same permanent ligation / 30 days recovery protocol.  
All morphological analyses were supported by echocardiographic determination of 
LV function. The assessments were performed before and during the recovery period after 
two, 14, and 30 days, respectively. Regional myocardial function was measured with the 
help of speckle-tracking strain analysis. 
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Results 
Permanent coronary ligation resulted in an equivalent injury in WT and SDF 
overexpressing mice. However, the outcome of cardiomyocyte-specific SDF 
overexpression was a reduction in infarct size and improved LV ejection fraction four 
weeks after myocardial infarction. This protection sustained when SDF was overexpressed 
for a period of at least 30 weeks (elderly mice). SDF overexpression markedly accelerated 
myocardial remodeling indicated by increased numbers of BrdU+ cardiomyocytes in the 
border- and scar area of the LV and an augmented apoptosis rate. Interestingly, we did not 
detect any capillary density difference in WT and SDF Tg mice after sham operation or 
permanent coronary ligation. 
Conclusion 
Our data indicated that cardiomyocyte-specific overexpression of SDF facilitates 
myocardial regeneration after permanent coronary ligation. Surprisingly, this effect was 
not related to an increase in vascularization but rather to a direct effect on cardiomyocyte 
proliferation. The number of new cardiomyocytes appears to be too small to explain the 
improvement in LV function detected by echocardiography; therefore, it is likely that other 
paracrine effects of SDF contributed to the increase in ejection fraction. 
 
MATERIAL AND METHODS 
Experimental protocol 
To investigate the early and late effect of chronic SDF overexpression on 
myocardial regeneration we performed two sets of permanent ligation experiments, 
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gathering hearts for pathology evaluation after one and four weeks, respectively (as 
described below, Figure 10).  
WT and “high” expressing SDF (SDF high) Tg mice were monitored during both periods, 
while experiments in “low” expressing SDF Tg mice (SDF low) were only performed with 
a four-week recovery period. To confirm whether the duration of SDF overexpression will 
affect the size of injury, we performed an additional set of experiments in SDF high mice 
for more than 30 weeks (i.e. mice of 45-50 weeks of age). 
 
Figure X Experimental protocol of permanent coronary ligation experiments 
C57 / B6 WT, SDF low, and SDF high mice (12 weeks old / four weeks off dox) were used 
to perform the permanent ligation experiments. Mice were followed for either one or four 
weeks after permanent coronary ligation prior to pathological examination. BrdC, 5-
Bromodeoxycytidine was used as DNA labeling agent, which is deaminated prior to 
incorporation into DNA as BrdU, because its greater solubility in PBS and a slower rate of 
metabolism in rats and mice resulting in larger intracellular supply. Echo, 
Echocardiography performed before ligation, at day 2, 7, 14, and 30, respectively. 
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Assessment of myocardial injury after permanent ligation 
TRIPHENYLTETRAZOLIUM-CHLORIDE- (TTC) STAINING 
Triphenyltetrazolium staining was used to identify viable and dead myocardium. 
The staining principle is based on the presence of membrane bound diaphorases that use 
NADH (NADPH) as electron donor to reduce tetrazolium chloride to a red formazan 
pigment, allowing the distinction between viable and dead tissue.70 We assessed the initial 
injury 72 hours after permanent coronary ligation: Mice were anesthetized with 
pentobarbital (0.4 mg i.p.), the chest was opened and hearts were arrested in diastole by 
injection of 0.1 ml Cd-KCl (0.1M Cd, 3 M KCl) into the LV cavity. The heart was removed 
and the aorta was cannulated with a 14-gauge blunted needle and perfused retrograde using 
the Langendorff method to remove intracoronary blood. The coronary bed was perfused 
with heparin (100 IU) containing Krebs-Henseleit buffer at a constant rate (1 ml / minute) 
for ten minutes. Thereafter, the perfusion solution was changed to 10% Evans blue (E2129, 
Sigma Aldrich, St. Louis, MO, USA) solution to stain the remote area. After infusing one 
to two milliliters at a constant rate (0.5 ml / minute), excessive blue stain was removed by 
washing the hearts in PBS. Subsequently, hearts were transferred to a heart slicer and cut 
into one millimeter cross-sections. The staining was finalized by incubating the sections in 
1% triphenyltetrazolium solution for 15 minutes at 37°C, demarking viable myocardium 
(red) from damaged myocardium (pale, unstained). To intensify the staining results, tissue 
sections were fixed in 4% paraformaldehyde for 20 minutes. The staining results were 
digitalized by a camera mounted on a surgical microscope. The infarct size was then 
measured by planimetry, taking both sides of each slice into account, and expressed as 
percentage of dry LV weight.  
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TRICHROME STAINING 
The sections were de-paraffinized and rehydrated to distilled water using a standard 
graded xylene-ethanol series before staining. The infarct size was measured after Masson’s 
trichrome (HT15-1KT, Sigma Aldrich, St. Louis, MO, USA) staining, based on the 
interaction of ionized acid dyes reacting with ionized basic tissue and distinguishing 
collagen, scar, and muscle fibers. After an overnight incubation of the tissue sections in 
Bouin’s solution to intensify the final coloration, the nuclei were stained with Weigert’s 
iron hematoxylin, and the cytoplasm and the muscle with Bierbrich scarlet-acid fuchsin 
solution (Sigma Aldrich, HT15-1). A subsequent treatment with phosphotugstic (Sigma 
Aldrich, HT15-2) and phosphomolybdic acid (Sigma Aldrich, HT15-3) removed the 
plasma stain (Bierbrich scarlet-acid fuchsin) from collagen, which then appeared paler than 
the muscle stain. Then an aniline blue solution, which has a molecular weight between the 
plasma stain and the poly-acids, was applied to mark collagen. After 15 minutes of 
incubation, collagen stained blue without affecting the plasma stain. Subsequently, the 
sections were rinsed in acetic acid, rendering the shades of color more delicate and 
transparent.71 Photos of the stained sections were digitally acquired on an inverted 
microscope equipped with a digital camera. The LV planimetry was performed using 
publicly available software (NIH Image J, 1.48s ver.) and the LV area, risk region, remote 
region, border zone, LV cavity area, and infarct zone were determined as previously 
described.3 To quantify the degree of LV dilatation and the degree of infarct wall thinning, 
the LV expansion index was calculated using a modification of the method of Hochman 
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Measurement of cardiac regeneration by chronic administration of BrdC 
To measure the cardiac regeneration 5-bromo-2 deoxycytidine (BrdC, MP 
Biomedicals, Solon, OH, USA) was injected i.p. daily for seven days, and afterwards 
continuously infused until the end of the experiment. BrdC is rapidly deaminated prior to 
incorporation into DNA as 5-bromo-2’-deoxyuridine (BrdU), a thymidine analogue 
frequently used to detect proliferation of cells that can be passed to daughter cells upon 
replication.73 The physical properties of BrdC (higher solubility in PBS and its slower 
metabolism in mice) made it more suitable for intracellular BrdU supply for DNA labeling 
in our experiments. During the first seven days after coronary ligation, BrdC (2 ug / g / h 
i.p.) was injected daily. After surviving the initial recovery phase, the mice were re-
anesthetized and an osmotic minipump (Alzet type 2004, Alzet, Cupertino, CA, USA) was 
implanted subcutaneously between the scapulae to deliver BrdC (0.7 ug / g / h) until the 
end of the experiment.74 Incorporated BrdU was determined by immunohistochemistry 
methods (see below). 
BrdU incorporation as an indicator of cell proliferation has been criticized because 
cells undergoing DNA repair might also incorporate BrdU into their DNA.75 However, the 
level of BrdU incorporation with DNA damage is orders of magnitude less than that during 
DNA synthesis and replication.76 The final number of BrdU positive cells reflected the 
entire amount of cells undergoing DNA repair and / or cell division. To provide additional 
support for DNA synthesis and cell division sections were also stained for Ki67 (VP-RM-
Equation 1 LV expansion index
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4, Vector labs, Burlingame, CA, USA): The nuclear antigen Ki67 is expressed in all phases 
of the cell cycle except for G0.77 Ki67 is not involved in DNA repair78 and therefore a 
specific marker for cells undergoing mitosis as mainly apparent in the late S phase and 
increased in G2 until pro- and metaphase. Measuring Ki67 positive cells in our samples 
allowed us to determine the number of dividing cells at the time of sacrifice. 
Detection of Apoptosis 
Heart failure as a consequence of myocardial infarction is characterized by 
progressive cell loss.79 Previous data suggest that SDF might abolish programmed cell 
death.80 Therefore, TUNEL staining was used to identify double-stranded DNA 
fragmentation within the scar, border, and remote zone after myocardial infarction. 
Echocardiography 
Echocardiographic studies were performed before the ligation experiment 
(baseline) and 72 hours, 14 days, and 30 days after the infarct to assess the initial injury 
and the progression to heart failure (14 days and 30 days, respectively) using a VEVO2100 
echocardiography system (FUJIFILM VisualSonics, Toronto, Ontario, Canada) equipped 
with a MS400 (18-38 MHz) cardiovascular ultra-high frequency linear-array transducer 
probe. To ensure good quality images for speckle-tracking based strain analyses, all images 
were acquired at a rate of more than 200 frames / second, providing an optimal temporal 
resolution and minimizing artifacts. The mice were anesthetized with isoflurane (2-3 
Vol.%) and the anterior chest was shaved. The mice were placed on a heated pad in the 
supine position and the body temperature was measured by a rectal probe to maintain 37°C. 
Throughout the study, the anesthesia depth was adjusted with isoflurane (~1 Vol%) to 
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achieve a heart rate between 450-500 bpm. Animals with a heart rate out of the target range 
were excluded from the analysis. Standard parasternal long- and short-axis views were 
performed to obtain two-dimensional, M-mode, and speckle-tracking analysis images.81 
An average of five cardiac cycles was used for each analysis. 
Strain analysis 
The strain is a dimensionless variable reflecting the deformation of the heart in 
circumferential, radial, and longitudinal dimension. As an angle-independent method the 
quantification is less operator dependent. The method is based on the estimation of velocity 
vectors by tracking segmental tissue motions in multiple planes and axes serially over the 
cardiac cycle, providing detailed information about global and regional LV function. 
Thereby, a negative strain reflects shortening (or thinning) while a positive strain reflects 
elongation (or thickening) of a LV wall segment. Based on the anatomic orientation of LV 
fibers the systolic radial strain results in positive values under physiological conditions, 
whereas the systolic longitudinal strain results in negative values. In addition, the temporal 
derivative of the strain (i.e. the strain rate) reflects the rate of deformation similar to the 
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The strain rate was measured in six different areas of the LV wall: The posterior 
and anterior wall were divided into a basal, middle, and apical segments. For each segment 
the radial and longitudinal strain rate was measured, allowing us to determine precise areas 
of increased or decreased contractility. 
Equation 2 LV strain rate
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The LV mass=1.05 x ([anterior wall thickness + LVEDD + posterior wall thickness]3 – 
LVEDD3) was calculated by M-mode cubic method where the specific gravity of cardiac 
muscle is 1.05 g / L.83 
Definition of border, remote zone, and scar area 
Three different areas of each cross section were evaluated: The border zone was 
defined as an area reaching one millimeter from the end of the scar towards “healthy tissue” 
in one direction and “scar tissue” in the opposite one. The remote zone represents the area 
of the none-infarcted ventricular wall between the border zones. The scar area is defined 
as the fibrotic area between the edges of the border zone (Figure 11).  
Immunuofluorescent staining 
As previously described, the sections were prepared except for the following 
modifications: The antigen retrieval was modified dependent on the target: For staining of 
c-kit and surface markers like CD45 we used a basic EDTA buffer (pH 8.0), as this buffer 
is suitable for detection of rare and sensitive antigens. In all other cases, we used citrate 
buffer (sodium citrate buffer, citrate buffer, pH 6.0). Staining for c-kit+ CSPCs and BrdU 
was performed as described above. Cardiomyocyte cross section area was determined after 
staining with a FITC-labeled wheat germ agglutinin antibody (WGA, Molecular Probes, 
Eugene, OR, USA). To quantify cardiomyocyte size, images were captured with a 40X 




Figure XI Example of ligated WT heart and cardiac-cross section 
A: Heart of a WT mouse four weeks after permanent ligation mounted on a perfusion 
cannula. The green arrow indicates the level of remaining blood visible through the 
thin, infarcted anterior wall.  Black bars indicate sectional area of four total sections of 
which section two and three were used for analysis. B: Typical cross section after 
trichrome staining. The blue marked area reflects the scar region. The area including 
the scar between the two blue bars marked the area at risk. The area between the which 




Myocytes with nuclei of round morphology were selected to ensure those with true 
cross sectional orientation were included and those at oblique angles which would skew 
data were excluded. The capillary density in the border and remote zone was determined 
after staining with the endothelium-specific, FITC conjugated isolectin B4 antibody 
(FL1201, Vector labs, Burlingame, CA, USA). The number of apoptotic nuclei was 
detected after TUNEL staining (DeadEnd TUNEL Fluorometric System, Promega, 
Madison, MI, USA). Cardiomyocytes were counterstained with α-sarcomeric actin (Sigma, 
St. Louis, MO, USA). 
Statistical analysis 
All data were expressed as mean±SEM and the differences were analyzed using 
unpaired Student’s t-test or a two-way ANOVA [group effect (i.e. genotype) and time 
effect (time after initiating SDF overexpression)], facilitating Bonferroni’s correction for 
multiple comparisons. The statistical significance was defined as P<0.05 or in cases of 
multiple comparisons adjusted by dividing 0.05 by the number of comparisons. The 
statistical analyses were performed using PRISM (Vers. 6.0e for MAC OSX, Graphpad 
Software, La Jolla, CA, USA). The immunopathology assessment was performed in one to 
two LV cross sections by confocal microscopy. The data represented in the analysis 
reflecting results of five to 15 images taken at 63X magnification for each area as described 
above. Per treatment group, the number of animals included in each staining step reached 




From the pool of mice undergoing ligation or sham operation, 18% died before the 
proposed end of the experiment and 13% were excluded due to technical problems (i.e. 
missed ligation, anesthesia complications) resulting in an overall survival rate of 69%. 
Reduction of myocardial injury 
Following the American Heart Association’s84 expert committee guidelines we 
measured the infarct 72 hours after permanent coronary ligation to ensure that the initial 
injury was consistent between the mouse strains (Figure 12). The LV weight of SDF high 
was significantly smaller compared to WT mice; nevertheless, we did not detect a 
difference in infarct size (WT: 36±3% vs. SDF high: 42±2% of the area at risk, P>0.05), 
suggesting that the initial injury was equivalent between both groups. Re-evaluation of the 
infarct size after one week revealed the same result [i.e. no difference in infarct size 
between WT (59±7%) and SDF high: 53±5% of the area at risk, P>0.05)] while the risk 
area was similar (WT: 49±8% vs. SDF high: 55±1% of the LV, Figure 13). In contrast, 
four weeks after permanent ligation the infarct size (percentage of LV) was significantly 
reduced in SDF high (13±2%) compared to WT (23±3%), P<0.01) and SDF low mice 
(23±5%, P<0.05), respectively. Despite the presence of the same scar size the infarct 
expansion index was almost significantly reduced in SDF low (1.7±0.2) compared to WT 
(2.4±0.4, P=0.07), reflecting an increased anterior (SDF low: 1.1±0.1 mm vs. WT: 0.8±0.1 
mm, P<0.05). Similar results were obtained in elderly mice overexpressing SDF for more 
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than 30 weeks: The infarct size was reduced from 24±4% (WT, n=5) to 8±2% of the LV 
(SDF high, n=5, p<0.01, Figure 14). 
  
 
















Improvement of LV function 
The echocardiographic evaluation in young and elderly mice revealed that 
expression in SDF low and SDF high mice neither changed the regional wall (data not 
shown) nor the global LV function (Figure 15). However, in contrast to a progressive 
reduction in the LV function in WT mice, SDF mice maintained the cardiac function on 
the level reached two days after infarction, resulting in a significant difference in the 
 
Figure XIV Morphometry in WT, SDF low and SDF high mice four weeks after 
permanent coronary ligation 
The permanent ligation resulted in significant reduction in anterior wall thickness in WT 
mice compared to SDF low and SDF high, and a significant reduction of infarct size and 












































































































































ejection fraction (WT: 29±4% vs. SDF high: 47±5%, P<0.05) at the end of the experimental 
period. The regional wall motion was improved indicated by a trend towards an increased 
wall thickening fraction of the anterior wall (Figure 16). In addition, regional changes 
within the LV were analyzed by strain rate (Figure 17) indicating increased longitudinal 
and radial strain rate of the mid and apical wall sections of the anterior, infarcted wall 




Figure XV Baseline cardiac function in mice overexpressing SDF at five weeks and 
more than 30 weeks 
A-F: LV function variables in WT and SDF high mice overexpressing SDF for five weeks. 
G-L: LV function variables WT and SDF high mice overexpressing SDF for more than 30 
weeks. EDA: end-diastolic area, ESA: end-systolic area, EDV: end-diastolic volume; 
















































































































Figure XVI LV function in WT and SDF high mice before and at different time points 
after permanent coronary ligation 
LV-Vd: end-diastolic LV volume, LV-Vs: end-systolic LV volume, EF: left-ventricular 





Figure XVII Examples of radial and longitudinal strain in WT and SDF 
overexpressing mice before and four weeks after coronary artery ligation 
A: Six different areas were used for longitudinal and radial strain rate analysis. B: Example 
of radial and longitudinal strain rate of a WT mouse before (left) and four weeks after 
coronary ligation (right), which resulted in asynchronous contraction. C: Color code used 







































































Increased cell turnover, but unchanged capillary density 
The staining for BrdU showed that the number of BrdU+ cardiomyocytes increased in the 
remote, border, and scar area of the LV in SDF high mice (Figures 19, 20, and 21). The 
data were confirmed by an increased number of Ki67+ cardiomyocytes four weeks after 
 
Figure XVIII Regional wall function measured by speckle trecking 
Longitudinal and radial strain rate (SR) in apical, middle (mid) and base section of anterior 
and posterior wall in WT and SDF high mice at baseline and at different time points after 
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myocardial infarction (Figure 22). Measurement of the capillary density indicated no 
difference between WT and SDF high, sham and permanent coronary ligated mice (Figure 
23). Surprisingly, similar to the increase in cell proliferation (BrdU staining, Ki67 staining) 
we detected an increase in TUNEL+ nuclei after one and four weeks in SDF high, reflecting 
an increase in apoptosis (Figure 24). However, cardiomyocyte cross-sectional area was 
smaller in SDF high mice than in WT controls, indicating less hypertrophy four weeks after 













Figure XIX BrdU+ / α-sarcomeric actin+ cardiomyocytes in the border and remote 
zone four weeks after myocardial infarction in SDF high and WT mice 
A: Representative cross-section with inserts reflecting BrdU+ / α-sarcomeric actin (αSA)+ 
cardiomyocytes in border- and scar area (yellow arrows). B: Number of BrdU+ 
cardiomyocytes expressed as percent of all cardiomyocytes. C: typical cross-section 
within the border-zone indicating the presence of cardiomyocytes with (yellow arrow) and 
without nuclei (red arrows). D: BrdU+ nuclei, expressed as cardiomyocyte nuclei. (BrdU+: 
FITC=green, αSA: TRITC=red, DAPI=blue). N=10-12, **,p<0.01, ***, p<0.001, 





Figure XX BrdU+ cardiomyocytes in the scar area of WT and SDF high mice four 
weeks after infarction 
A: representative cross-section of BrdU (green), DAPI (blue) and α-sarcomeric actin (red) 
stained sections SDF high mice (A, top panel, SDF high) and WT (A, lower panel) mice. 





































Figure XXI Dividing cardiomyocyte in the border zone of a SDF high overexpressing 
mouse 
Arrow heads indicate nucleus undergo karyokinesis, while arrow indicate the nucleus of a 








Figure XXII Ki67+ cardiomyocytes in the remote and border zone of WT and SDF 
high mice four weeks after infarction 
A: representative example of an area at the border zone of a SDF high mouse, showing a 
dividing cardiomyocyte. B: Number of Ki67+ / α-sarcomeric actin+ in the border and 





Figure XXIII Capillary density in WT and SDF high mice after sham operation and 
four weeks permanent ligation in the remote and border zone 
A: Capillary density in sham operated animals. B: Capillary density in mice underwent 
permanent coronary ligation (N=12-14). 
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Figure XXIV TUNEL+ nuclei one and four weeks after permanent ligation 
A: Representative cross section through a SDF high heart with images of TUNEL+ section 
in scar, border, and remote zone one week after permanent ligation. B, C: Quantitative 
analysis of TUNEL+ nuclei (yellow arrows) in WT and SDF high mice in each area one 























Figure XXV Wheat-germ agglutinin staining for measurement of myocytes cross-
sectional area 
Wheat-germ agglutinin staining of representative areas of remote (left) and border-zone   

















Figure XXVI Histogram of cardiomyocyte cross-sectional area  
Upper panel shows the number of myocytes of each specific size (logarithmic scale) in the 
border (left side) and the frequency distribution (right side, median [range]) in the border 
zone. The lower panel shows the corresponding results in the remote zone. There was a 
slight difference between WT and SDF high mice showing smaller myocytes in the border 
zone. Total number of myocytes analyzed in the border zone (WT: 925, SDF high: 974) 
and in the remote zone (WT: 851, SDF high: 1148). *, p<0.05, Mann-Whitney test. 
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CONCLUSION 
In conclusion, our data clearly indicate that in a permanent coronary artery ligation 
model, SDF overexpression fails to protect against ischemic injury. The key feature of a 
permanent coronary artery ligation model is the absolute lack of oxygen and nutrition 
support to the ischemic area. As the myocardium of mice lacks significant collateral 
circulation compared to other species (i.e. canine, human)85 the survival of myocardium 
due to collateralization in this model is very unlikely. Importantly, we found increased 
myocardial regeneration already within four weeks after the injury, as indicated by BrdU 
and Ki67 staining. Surprisingly, regeneration was accompanied by increased apoptosis. 
Cardiomyocytes stained positive for BrdU were detectable as early as one week after 
myocardial infarction, partially featuring already an adult cardiomyocyte phenotype 
(Figure 27).  
Different possible mechanisms might be responsible for this impressive 
regeneration potential: Previous work suggested that even adult cardiomyocytes have the 
potential to undergo cell division initiated by either inhibition of p38 MAP kinase86 or 
GSK-3β inhibition.87 Furthermore, circulating as well as resident c-kit+ progenitor cells 
might be differentiated towards a cardiomyocyte phenotype. Interestingly, we detected a 
significant increase in apoptosis in SDF overexpressing mice one and four weeks after 
myocardial infarction. These data contrast published work in myeloid progenitor cells64,88 
in which apoptosis was inhibited in the presence of SDF.  
The overexpression of SDF prevents a decline of global and regional LV function 
after myocardial infarction. About 20% of all cardiomyocyte nuclei were BrdU+, 
representing about 4% of all cardiomyocytes regenerated in the border zone. The volume 
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of newly generated cells appears to be too small to cause a significant increase in LV 
function, suggesting that secreted SDF also acted as a paracrine factor increasing 
myocardial contractility.89 However, neither short-term (five weeks) nor long-term (more 
than 30 weeks) SDF overexpression affected the myocardial function in sham-operated, 
non-infarcted, mice. This might suggest that cardiomyocytes changed their sensitivity 
towards SDF after myocardial infarction by accelerating cardio-protective signaling 
pathways.  
SDF / CXCR4 was identified as a key factor in the recruitment of stem cells to areas 
of tissue injury in multiple organ systems. 
 
Figure XXVII Adult phenotype of new generated myocyte one week after infarction 
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Interestingly, our data did not confirm the overall finding that SDF / CXCR4 acts 
as a molecular hub modulating neo-angiogenesis.90 SDF not only promotes 
revascularization by engaging with CXCR4 expressed on the vascular cells but also 
supports mobilization of pro-angiogentic CXCR4+VEGFR1+ hematopoietic cells, thereby 
accelerating revascularization of ischemic organs. Shahin Rafii introduced the concept that, 
by modulating plasma SDF levels, the CXCR4 antagonist AMD3100 acutely promotes, 
while chronic AMD3100 treatment inhibits, mobilization of pro-angiogenic cells.  
In contrast to most of the previous studies suggesting neovascularization after SDF 
treatment, in our model SDF was only overexpressed in cardiomyocytes and our 
intervention was not accompanied by simultaneous infusion of hematopoietic stem/ 
progenitor cells or their mobilization from the bone marrow (i.e. by administration of G-
CSF or AMD3100) as previous described. Therefore, our data suggested that 
cardiomyocytes-specific SDF overexpression might primarily act as a para- and / or 








SUMMARY AND FUTURE RESEARCH DIRECTIONS 
Several different studies have been performed using SDF as chemokine to 
accelerate cardiac regeneration after myocardial infarction. However, less was known 
about the direct effect of chronic cardiomyocyte-specific expression of SDF cardiac 
regeneration and regulation of cell proliferation after myocardial infarction. Our results can 
be summarized as follows:  
 This is the first study showing that cardiomyocyte-specific overexpression of 
SDF results in improved LV function, decreased myocardial infarction, and 
increased generation of new cardiomyocytes. 
 We found no difference in myocardial infarct size and LV function directly after 
permanent ligation (i.e. three and seven days), which suggested the same initial 
injury between WT and SDF overexpressing mice. 
 LV function remained unchanged despite cardiomyocyte-specific 
overexpression of SDF for five and 30 weeks, respectively. 
 SDF overexpression resulted in a gene copy-number dependent increase of 
CK1α and phosphorylation of AKT affect two important factors of cardiac 
regeneration: An increase in CSPC numbers within the heart of SDF high mice, 
and an increase of cardioprotective signaling.  
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 However, BM function seems to be diminished as the number of leukocytes 
decreased after five and 30 weeks exposure to increased cardiac SDF levels, 
respectively. In contrast to previous published data, we did not see an increase 
in neo-vascularization after SDF overexpression but an increase apoptosis 
indicated by more TUNEL+ cells. 
As discussed above stem cell therapy currently appears to be the most attractive 
approach to generate new myocardium after an infarction. Nevertheless, some limitations 
apply as mentioned above, and therefore, alternatives are needed.  
Here we used a model of cardiac-specific SDF overexpression and detected a 
marked increase in cardiac regeneration with a reduction in infarct size. Some special 
findings should be further annotated: 
What is the origin of the new cardiomyocytes? 
We detected a significant increase in cardiac regeneration including a marked 
increase in BrdU+ or Ki67+ cardiomyocytes after permanent coronary ligation. The 
question becomes whether these are newly generated cardiomyocytes or a sort of 
differentiated, cardiac linage committed progenitor cells. Unfortunately, our study does not 
allow us to determine the origin of these newly formed cells. As extensively reviewed by 
Dr. Pierro Anversa’s group91 and others, several explanations are possible:  
a) Fate mapping studies using dilution of GFP labeling as indicator for newly 
formed cardiomyocyte, indicated 35% of the cardiomyocytes in the border zone and 28% 
in the remote-zone were newly generated, compared to 14% in sham operated mice.74 In 
contrast to Dr. Anversa’s group, Richard Lee suggests that pre-existing cardiomyocytes are 
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the primary source of cell replacement after injury.76 Using in vitro experiments, Keating 
and colleagues providing evidence that cardiomyocyte division occurs by either p38 MAP 
kinase inhibition86 or blockade of GSK-387 resulting in newly formed adult mammalian 
cardiomyocytes. 
b) C-kit+ progenitor cells are considered as cardiac-specific stem cell source, giving 
rise to oligolineage progenitors, which after losing their self-renewal ability and 
withdrawal from cell-cycle, eventually become mature cardiomyocytes.92,93 
c) Finally, reprogramming and trans-differentiation have been proposed as sources 
for new cardiomyocytes. Reprogramming of somatic cell (i.e. cardiac fibroblasts) towards 
cardiac lineage requires complex modulation using several transcription factors94,95 which 
appears unlikely in the model described in this thesis.  
As chemoattractant, SDF has the potential ability to recruit hematopoietic stem 
cells to the infarct area, where those cells de-differentiate to myocytes or vascular cells. 
Although we cannot rule out this possibility, the absence of EPC mobilization after 
myocardial infarction in SDF Tg mice suggests that circulating cells most likely are not 
responsible for the improved function and generation of new cardiomyocytes seen in our 
experiments. 
Cell cycle control by SDF appears to be different between cardiomyocytes and CSPCs. 
Previous published data suggest that SDF mediates CSPC quiescence through a 
CK1α dependent mechanism, as administration of CK1α resulted in decreased CSPC 
proliferation. The western blot analysis from SDF overexpressing hearts in this study 
revealed a gene-copy number dependent increase in CK1α, which was accompanied by an 
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increased number of CSPC in sham-operated animals. However, the number of BrdU+ / c-
kit+ cells within the heart was similar to the WT controls, indicating decreased CSPC 
proliferation and confirming our previous in vitro work.46 Interestingly, besides the marked 
increase of BrdU+ / α-sarcomeric actin+ cardiomyocyte numbers in the border zone after 
myocardial infarction, we also detected in the non-ischemic region accelerated 
proliferation of cardiomyocytes. Assuming that CK1α expression in this region of the heart 
is similar to sham-operated animals, the data would suggest that cardiomyocyte 
proliferation is subject to a different regulatory pathway, which might or might not include 
CK1α. 
Besides the increase in BrdU+ and Ki67+ cardiomyocytes one and four weeks after 
myocardial infarction, we detected a significant increase in TUNEL+ nuclei, indicating 
increased apoptosis and cardiac remodeling:  
Increased apoptosis 
In contrast to previously published work suggesting anti-apoptotic properties of 
SDF, these findings came as a surprise, but might be explained by the prolonged exposure 
of circulating cells towards SDF in weeks prior to myocardial ischemia. Different authors 
suggested that circulating CD8+,96 CD4+,97 and specific tumor cells,98,99 undergo apoptosis 
after prolonged exposure to SDF. Interestingly, even concentrations as low as 10 ng / l 
might induce apoptosis dependent on the duration circulating cells are exposed to the 
chemokine.97 The molecular mechanism triggering the cell death is not quite understood, 
but Herbein96 detects after a relative high concentration of SDF (i.e. 1 µg / l) a progressive 
increase of CD95 antigen expression on the cell surface as well as CD95L within the cell. 
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Others describe up-regulation of TNFα or TNF-R which led to cell death after secondary 
exposure to SDF. 
Finally, we did not find any difference in capillary density between WT and SDF 
overexpressing mice: 
SDF overexpression did not promote neovascularization 
SDF is identified to directly participate in new blood vessel formation in vitro by 
preventing EPC apoptosis100,101 and in vivo by inducing vasculogenesis. Mobilization of 
pro-angiogenic hematopoietic cells can be increased by either elevating SDF levels or by 
blocking CXCR4 by AMD3100.102,103 However, dynamics of mobilization between both 
methods are quite different as injection of AMD3100 rapidly mobilized hematopoietic stem 
cells, pro-angiogenic cells, and EPCs, while SDF mediated mobilization requires several 
days. Petit and colleagues suggest a “niche-dependent mobilization model”, in which 
different “geographical microenvironments” are stimulated by both methods:90 The easy 
accessible perivascular niche, readily available to release hematopoietic stem cells, will 
respond quickly to an CXCR4 inhibition. In contrast, SDF mediated release of 
hematopoietic stem cells from the stromal or osteoblastic niches within the BM require a 
cascade of events and therefore requires several days to release hematopoietic stem cells 
into the circulation.104  
Although we did not reach the significance level, the number of EPCs was reduced 
in the BM sample and the peripheral blood, respectively, which would suggest a diminished 
pool of EPCs in the Tg mice, reflected by the absence of EPC mobilization 72 hours after 
permanent ligation. 
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Furthermore, it has been reported that knockdown of CK1αLS inhibits vascular cell 
proliferation in various isolated vessels (i.e. human umbilical vein endothelial cells, human 
coronary artery smooth muscle cells, and human coronary artery endothelial cells).105 As 
CK1αLS is thought to function antagonistically to its related cytosolic splice forms CK1α 
and CK1αS, which are known to negatively regulate pro-proliferative pathways,106,107 SDF 
mediated overexpression of CK1α might also be responsible for diminished 
revascularization after myocardial infarction. 
LIMITATIONS 
The conclusion that SDF overexpression facilitates increased regeneration after 
myocardial infarction resulting in improved function was based on the fact that we found 
an increase in BrdU+ cardiomyocytes in the border-zone and in the scar area four weeks 
after myocardial infarction. As with many methods, BrdU incorporation as marker of cell 
division is recently challenged by the fact that theoretically, the replacement of thymidine 
with BrdU during DNA repair might also result in positive stained nuclei which could 
falsely interpreted as a cell undergo karyokinesis. In a recent study Richard Lee 
demonstrates that 15H thymidine incorporation is two magnitudes higher in cells 
undergoing cell division than after H2O2 induced DNA damage and DNA synthesis.76  
Our results might reflect SDF mediated increase in DNA synthesis after hypoxia 
induced cell injury without increased cell proliferation. However, Masson’s trichrome 
analysis after one week indicated that 30% of the LV were scar tissue, similar between WT 
and SDF high mice. While the amount of scar tissue was significantly diminished in SDF 
 86 
high mice (13%) the scar size remained the same in WT mice four weeks, suggesting the 
generation of new, viable myocardium in the SDF Tg hearts. 
The combination of both observations (i.e. higher magnitude of BrdU incorporation 
in myocytes undergo karyokinesis and a significant reduction in infarct size) lead to our 
conclusion that cardiomyocyte specific overexpression of SDF facilitates regeneration of 
myocardium after permanent coronary ligation. 
FUTURE DIRECTIONS 
For the first time, our experiments provide evidence that the regeneration profile of 
the heart is facilitated after permanent coronary ligation by overexpressing SDF in the 
cardiomyocytes, which resulted in newly generated myocytes, increased LV function, and 
reduced myocardial infarct size. Further studies are needed to determine the role of CK1α 
in cardiomyocyte and stem cell proliferation to determine whether it is suitable for gene 
therapy directly targeting myocytes renewal. The effect of chronic myocyte-specific SDF 
overexpression on BM homeostasis needs to be further evaluated as a depression of the 
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Since 2013 Review editor “Frontiers in Physiology, Oxidant Physiology” 
Since 2011 Annual abstract reviewer for the AHA scientific sessions, basic science 
abstracts “Ischemia Reperfusion Injury” section 
2014  Ad hock Reviewer: 
  * BMC Anesthesiology 
  * TAAP – Toxicology and Applied Pharmacology 
2013  Ad hoc Reviewer:  
  * American Journal of Cardiology 
  * TAAP – Toxicology and Applied Pharmacology 
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2011  Ad hoc Reviewer:  
  * American Journal of Cardiology 
  * Cardiovascular Diabetology 
2010  Journal of Cellular and Molecular Neurobiology  




Since 2013 Editorial Board of Frontiers in Oxidant Physiology – Review Editor 
Since 2013 Editorial Board BioMed Research International - Anesthesiology 
 
TEACHING: 
Since 2006 Scheduled Classes for Medical Students and Residents 
2012  ACLS lecturer for Anesthesia Residents 
2012 Course Director, Initiator, Program presenter, 1st Louisville Airway Day, 
May 24th 2012, Louisville, KY, USA (CME accredited program) 
2010 ASA Instructor of Difficult Airway Management (ASA annual meeting, 
San Diego, CA, USA) 
Since 2009 Lectures for medical students and Ph.D. graduates in the Department of 
Pharmacology at the University of Louisville, KY, USA (4 hours/ year) 
Since 2008 Lectures for medical students in the Department of Physiology and 
Biophysics at the School of Medicine, University of Louisville, KY, USA 
(8 hours/ semester) 
Since 2006 Regular lectures for residents of the Department of Anesthesiology and 
Perioperative Medicine, University of Louisville, Louisville, KY, USA 
2004-2005 Lecture for final year medical students in Anesthesiology, Department of 
Anesthesiology, University Hospital Düsseldorf, Germany 
1999-2001 Clinical tutor for medical students in emergency medicine, Department of 
Anesthesiology, University Hospital Düsseldorf, Germany 
1995-1997 Medical student tutor for cardiac and respiratory physiology, Department of 
Physiology, University of Düsseldorf 
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Predoctoral Students supervised and mentored:  
Since 1999 Laboratory tutor for medical students during their work for the thesis to 
doctorate 
H. Scharbatke   -  2004-2007  -  magna cum laude 
F. Hoetterkes  - 2005-2008 - magna cum laude 
S. Dettwiler  - 2007-2009 - magna cum laude 
C. Favoccia  - 2007  -  pending 
W. Brown (M.S.) - since 2009 
F. Memon (M.S.) - 2010-2011 
T.B. Wright (M.S.) - 2010-2013 
 
Mentor and Advisor of clinical research fellows 
Ragu Govinda   (2006-2008) 
Anton Grankin   (2008-2010) 
Alexander Bautista   (2009-2010) 
Sunitha Kanchikandadai  (2010-2011) 
Sahil Chabra    (2011-2013) 
 
ABSTRACTS AND PRESENTATIONS: 
 
Oral Presentations: National/ International Meetings 
1. Obal D: Perioperative Administration of ondansetron or dolasetron does not 
lengthen QT interval. Outcomes Research Meeting at the American Society of 
Anesthesiology Annual Meeting, Washington, DC. 10/ 7/ 012 
2. Obal D: Fiberoptic Intubation, 1st Difficult Airway Course, Paris Simulation 
Center, University of Louisville, KY, May 12th, 2012 
3. Obal D: Perioperative Use of Statins, Annual Kentucky Society of Anesthesia 
Spring Meeting, Marriott Cincinnati at Rivercenter, Covington, KY, March 24th, 
2012 
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4. Obal D: Effect of Storage Time on Outcome after Massive Blood Transfusion. 
Outcomes Research Meeting at the American Society of Anesthesiology Annual 
Meeting, San Diego. 10/ 7/ 010 
5. Obal D, Schlack W: Intraoperative myocardial ischemia – what should I do ?; TED 
session at the annual meeting of the German society of Anesthesiology 04/ 7/ 005 
6. Obal D:  Organprotection by anesthetic preconditioning. Scientific meeting of the 
outcome research department, University of Louisville, KY, USA 02/ 1/ 005  
7. Obal D: Prevention and treatment of perioperative myocardial ischemia 
8. What the anesthesiologist should know. Didactic lecture for the residencies of the 
Department of Anesthesiology, University of Louisville, KY, USA. 02/ 7/ 005 
9. Obal D: Perioperatives Nierenversagen; Didactic lecture 04/ 004 Department of 
Anesthesiology, University Hospital Düsseldorf, Germany 
10. Obal D, Fräßdorf J, Müllenheim J, Preckel B, Schlack W: Rolle der 
Opiatrezeptoren bei der Morphin - induzierten späten Präkonditionierung. 
Anästhesiologie & Intensivmedizin 2003; 44 FV 109.6. 
11. Obal D, Müllenheim J, Preckel B, Thämer V, Schlack W: How do administration 
time and concentration affect the cardioprotection by sevoflurane against 
reperfusion injury? Anesthesiology 2001; 95, A682. 
12. Obal D, Müllenheim J, Scharbatke H, Thämer V, Schlack W: Two minutes of 
sevoflurane administration are enough to protect the heart against reperfusion 
injury. Eur J Anaesthesiol 2001;18:A162. 
13. Obal D, Preckel B, Müllenheim J, Thämer V, Schlack W: Einfluss der 
Konzentration und Applikationsdauer von Sevofluran auf die Ausdehnung des 
Reperfusionsschadens des Herzens. Anästhesiologie & Intensivmedizin 
2001;42:877. 
14. Obal D, Preckel B, Hoff J, Thämer V, Schlack W: Einfluß einer Stellatumblockade 
auf die Ventrikelfunktion - Studie an wachen Hunden. Anästhesiol Intensivmed 





Oral Presentations: Local/ Regional Meetings 
Grand Round presentations at the University of Louisville, Department of 
Anesthesiology: 
 Obal D: Grand round, Department of Anesthesiology & Perioperative 
Medicine: Perioperative Lung Function; August 22nd, 2013 
 Obal D: Grand round, Department of Anesthesiology & Perioperative 
Medicine: Nitrous oxide – ENIGMA trial and other mysteries; July 7th, 2013 
 Obal D: Grand round, Department of Anesthesiology & Perioperative 
Medicine: QTc interval – neglected by anesthesiologists; August 3rd, 2012 
 Vessel E, Obal D: Grand round, Department of Anesthesiology & Perioperative 
Medicine: Repeat Operation on a Traumatic Hemorrhage; April 27th, 2012  
 Obal D : Grand round Department of Anesthesiology & Perioperative 
Medicine: “Introduction to ROTEM” June 2011 
 Obal D : Grand round Department of Anesthesiology & Perioperative 
Medicine: “Introduction to TEG” February 2011 
 Bo Hargett, Obal D. M&M Conference: “Why so hypotensive?” December, 
13th 2010 
 Obal D. The perioperative ischemic evaluation-2 (POISE-2) trial or “What’s 
new in the protection against perioperative infarction in patients undergoing 
non-cardiac surgery?” November, 8th 2010 
 Obal D. "Blood transfusion - do we need to change our current practice?" July 
6th 2009 
 Obal D. M&M Conference: Rush in the morning – the 5.30 am case. March 
2nd, 2009 
 Obal D, Lenhardt R, Turan A, Akca O. Research at the Department of 
Anesthesiology and Perioperative Medicine. May 18th, 2008 
 Lenhardt R, Obal D. Hemorrhagic Shock & Massive Transfusion - Standard 
Procedure at the UofL Hospital, March 10th, 2008 
 Obal D. Anesthesia and coagulation disorders. What the Anesthesia Provider 
Should Know ! April 14th, 2008 
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 Obal D. The ENIGMA II Trail. “Nitrous Oxide Anesthesia and Cardiac 
Morbidity after Major Surgery”. May 17th, 2007 
 Obal D, Henson L. Perioperative and Anesthetic Care for Trauma Patients, 
October 9th, 2006 
 Obal D. Anesthesia for emergency triplet A surgery. July 13th, 2006 
 
Poster Presentations: National/ International Meetings 
1. Obal D, Yang D, Sessler DI: Perioperative administration of ondansetron or 
dolasetron is not associated with QTc prolongation. ASA Annual meeting Abstract 
2012, 12-A-3862-ASAHQ 
2. Obal D, Dai S, Keith R, Dimova N, Kingery J, Zheng Y-T, Zweier J, Velayutham 
J, Prabhu S, Li Q, Conklin D, Bhatnagar A, Bolli R, Rokosh G: Overexpression of 
cardiomyocyte-specific extracellular superoxide dismutase increases nitric oxide 
bioavailability and reduces infarct size after ischemia/ reperfusion. Circulation 
2010 AHA Annual meeting, Chicago 
3. Bautista A, Brown B, Sessler D, Wadhwa A, Obal D: Effect of storage time of 
blood transfusion products on outcome in massive transfusion situations. 
Anesthesiology 2010, A1515 
4. Kasuya Y, Govinda R, Obal D, Turan A, Sessler DI: Effect of Aminophylline on 
Loss of Consciousness, BIS, and Propofol Requirement in Human Volunteers. 
Anesthesiology 2007; 107: A521 
5. Obal D, Favoccia C, Dettwiler S, Preckel B, Schlack W: Desflurane 
Postconditioning Reduces Renal Reperfusion Injury Anesthesiology 2005; 103: 
A337 
6. Fräßdorf J, Weber NC, Toma O, Obal D, Kojda G, Preckel B, Schlack W: Opioide 
receptors are mediators of late cardioprotection – involvement of the nuclear 
transcription factor B Cardio-Visionen - Symposium der Nordrhein-
Westfälischen Akademie der Wissenschaften, 2004, 1: 149 
7. Dettwiler S, Obal D, Favoccia C, Preckel B, Schlack W: Preconditioning induced 
by the volatile anaesthetic sevoflurane did not improve renal function after 
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ischaemia and reperfusion. Pflügers Arch Eur J Physiol 2004, Deutscher 
Physiologen Kongress 
8. Toma O, Weber NC, Wolter JI, Obal D, Preckel B, Schlack W: Die Desfluran-
induzierte Präkonditionierung wird über eine zeitabhängige Aktivierung der PKC-
ε und ERK-2 vermittelt. Anästhesiologie & Intensivmedizin 2004, 45: 691-718 
9. Pakulla MA, Obal D, Seidel D, Loer SA: Salzsäure-induzierte Lungenschädigung 
– Effekte einer frühen partiellen Flüssigkeitsbeatmung auf den Gasaustausch und 
das Überleben von Ratten. Anästhesiologie & Intensivmedizin 2004, 45: 691-718 
10. Weber NC, Toma O, Wolter JI, Obal D, Schlack W, Preckel B: Xenon induziert 
eine pharmakologische Präkonditionierung des Rattenherzens in vivo über eine 
Induktion der PKC-ε und p38 MAPK. Anästhesiologie & Intensivmedizin 2004, 
45: 691-718 
11. Toma O, Obal D, Weber NC, Dettwiler S, Preckel B, Schlack W: Zeitlicher Verlauf 
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Rattenherz in vivo. Anästhesiol Intensivmed Notfallmed Schmerzther 2004; DAK: 
PO-1-3.3. 
12. Ley S, Obal D, Dettwiler S, Preckel B, Schlack W: Effekt von Sevolfluran-
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Anästhesiol Intensivmed Notfallmed Schmerzther 2004; DAK: PO-1-3.2. 
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preconditioning through protein kinase C activation depends on isoflurane 
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both ? Eur J Anaesthesiol 2003; 20 (Suppl. 30), A231. 
19. Pakulla MA, Obal D, Seidel D, Loer SA: Partial liquid ventilation in acid-induced 
lung injury - effects of immediate and delayed initiation. Intensive Care Med 2003; 
29 (9 Suppl.), 559 
20. Pakulla MA, Obal D, Loer SA: Intraarterielles Blutgasmonitoring bei Ratten. 
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of inhalational anesthetics in dogs with severe heart failure. Anesth Analg. 
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27. Obal D, Preckel B, Scharbatke H, Thämer V, Schlack W: Is the protective effect 
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34. Preckel B, Schlack W, Gonzáles M, Obal D, Barthel H, Thämer V: Influences of 
Angiotensin II AT1 receptor antagonism on ischaemia / reperfusion injury of the 
dog heart in vivo. Pflügers Arch Eur J Physiol 1998;435. 
35. Gonzáles M, Preckel B, Schlack W, Obal D, Barthel H, Thämer V: Einfluß einer 
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 Obal D, Hu X, Dimova N, Brittian K, Book M, Guo Y, Bhatnagar A, Bolli R, 
Rokosh G: Inducible, cardiomyocyte-specific transgenic stromal cell derived 
factor 1 expression facilitates cardiac regeneration after permanent coronary 
ligation in mice. The cardiovascular forum for promoting centers of excellence 
and young investigators. International Academy of Cardiovascular Science 








NIH COBRE Grant A. Bhatnagar, Ph.D. (PI)                       04/ 1/ 9-present 
Center of excellence in diabetes and obesity research (Collaborator: 15% time support) 
The specific objective of the Center is to develop a basic and clinical understanding of the 
molecular mechanisms of diabetes and obesity and how they contribute to the burden of 
cardiovascular disease. In this focus I am studying the impact of hyperglycemia on cardiac 
reparative potential by mesenchymal and cardiac specific stem cells and whether 
modulation of cardiac environment increases regeneration tendency in diabetes.    
 
CLINICAL SERVICE: 
I provide general anesthesia services in the main operating room at the University of 
Louisville Hospital, covering general surgery, vascular surgery, neurosurgery, 
endovascular procedures, oncology surgery, liver surgery, ENT surgery, OB/ YN surgery 
and procedures, cardiovascular and thoracic surgery, trauma surgery. The University of 
Louisville is a level one-trauma center; therefore, orthopedic surgery and trauma surgery 
procedures are a major focus of our work, including regional anesthesia procedures as 
well as emergency procedures (rescue surgery after major trauma). The anesthesia service 
covers all cardiovascular resuscitations and difficult endotracheal intubations 24/  at the 
University Hospital. My call schedule includes six to eight 12 hour call shifts including two 
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Peer reviewed paper: 
1. Houser P, Miller J, Obal D: A case of critical intra-operative tracheal stenosis 
complicated by tension pneumothorax and postobstructive pulmonary edema. Clin 
Anesthesia 2014; xy: xx-xy (submitted for publication) 
2. Obal D, Yang D, Sessler DI: Perioperative doses of ondansetron or dolasetron do 
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phys.2013.00295. 
4. Obal D, Dai S, Keith R, Dimova N, Kingery J, Zheng Y-T, Zweier J, Velayutham 
J, Prabhu S, Li Q, Conklin D, Bhatnagar A, Bolli R, Rokosh G: Overexpression of 
Cardiomyocyte-specific Extracellular Superoxide Dismutase Increases NO 
Bioavailability and Reduces Infarct size after Ischemia Reperfusion. Basic Res 
Cardiol 2012;107(6):305. doi: 10.1007/ 00395-012-0305-1. Epub 2012 Oct 26) 
5. Wadhwa A, Kandadai SK, Tongpresert S, Obal D, Gebhard RE: Ultrasound 
guidance for deep peripheral nerve blocks: a brief review. Anesthesiol Res Pract. 
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6. Turan A, Kasuya Y, Govinda R, Orhan-Sungur M, Obal D, Rauch S, Dalton J, 
Akça O, Sessler DI: The effect of aminophylline on loss of consciousness, 
bispectral index, propofol requirement, and minimum alveolar concentration of 
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7. West MB, Rokosh G, Obal D, Velayutham M, Xuan YT, Hill BG, Keith RJ, 
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Cardiac myocyte-specific expression of inducible nitric oxide synthase protects 
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8. Preckel B, Obal D, Müllenheim J, Hennes J, Heiderhoff M, Thämer V, Schlack W: 
Effects of halothane, sevoflurane and desflurane on the force-frequency relation in 
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9. Obal D, Rascher K, Favoccia C, Dettwiler S, Schlack W: Post-conditioning by a 
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10. Obal D, Dettwiler S, Favoccia C, Rascher K, Preckel B, Schlack W: Effect of 
sevoflurane preconditioning on ischaemia/ reperfusion injury in the rat kidney in 
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11. Weber NC, Toma O, Wolter JI, Obal D, Müllenheim J, Preckel B, Schlack W: The 
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32. 
12. Obal D, Dettwiler S, Favoccia C, Scharbatke H, Preckel B, Schlack W: The 
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Analg. 2005 Nov;101(5):1252-60 
13. Fräßdorf J, Weber NC, Obal D, Toma O, Müllenheim J, Kojda G, Preckel B, 
Schlack W: Morphine induces late cardioprotection in rat hearts in vivo: the 
involvement of opioid receptors and nuclear transcription factor kappaB. Anesth 
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ventilation in acute salt water-induced lung injury. Eur J Anaesthesiol. 2005 
Jul;22(7):536-40. 
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